Directed Evolution of Antibodies Against Complex Targets by Desai, Alec




Alec A. Desai 
A dissertation submitted in partial fulfillment 
 of the requirements for the degree of  
Doctor of Philosophy  
(Chemical Engineering) 




Professor Peter M. Tessier, Chair  
Associate Professor Nina Lin 
Associate Professor Anna Schwendeman 



































I would like to thank Dr. Tessier, my dissertation committee members, and members of 
the Tessier lab for their help with the work. I would also like to thank Scholar Space, UoM 












List of Figures vi 
Abstract viii 
 Introduction 1 
References 6 
 Rational Affinity Maturation Of Anti-Amyloid Antibodies With High Conformational 




Experimental Procedures 38 
Note 52 
Citation 52 
Data Availability 52 
References 53 








 Directed Evolution Of Potent Neutralizing Nanobodies Against SARS-CoV-2 Using 








 Conclusion 122 
 vi 
List of Figures 
 
Figure 1-1: Structure of an antibody ............................................................................................... 1 
Figure 1-2: Reformatting antibody into antibody fragments. ......................................................... 3 
Figure 2-1: Proposed method for systematically maturing the affinity and specificity of Aβ 
amyloid antibodies. ....................................................................................................................... 10 
Figure 2-2:  Design of AF1 antibody sub-library for affinity maturation that targets naturally 
diverse and solvent-exposed CDR sites with mutations that are common in human antibodies. . 13 
Figure 2-3: Summary of the results for sorting the yeast-displayed antibody library against Aβ 
fibrils. ............................................................................................................................................ 15 
Figure 2-4: Identification of sets of affinity-enhancing mutations using deep sequencing. ......... 17 
Figure 2-5: Identified antibody variants display increased affinity and high conformational 
specificity for Aβ fibrils. ............................................................................................................... 19 
Figure 2-6: Immunoblot analysis of the conformational and sequence specificity of the affinity-
matured Aβ antibodies. ................................................................................................................. 21 
Figure 2-7: Conformational epitope analysis of Aβ antibodies. ................................................... 23 
Figure 2-8: Immunoblot analysis of transgenic (5xFAD) and wild-type mouse brain samples 
using Aβ antibodies. ..................................................................................................................... 24 
Figure 2-9: Western blot analysis of 5xFAD and wild-type mouse brain samples using affinity-
matured Aβ antibodies. ................................................................................................................. 26 
 vii 
Figure 2-10: Immunofluorescence staining of 5xFAD and wild-type mouse brain sections using 
Aβ antibodies. ............................................................................................................................... 27 
Figure 2-11: Biophysical characterization of Aβ antibodies. ....................................................... 29 
Figure 2-12: Additional affinity maturation results in an Aβ antibody variant (97A3) with 
improved affinity, high conformational specificity and low non-specific binding. ..................... 31 
Figure 3-1: Illustration of novel QD based FACS selection for amyloid fibrils. ......................... 64 
Figure 3-2: Binding analysis of α-synuclein antibodies. .............................................................. 67 
Figure 3-3: Binding analysis of tau antibodies. ............................................................................ 69 
Figure 4-1: Summary of the discovery and affinity maturation of nanobodies against the spike 
protein of SARS-CoV-2. ............................................................................................................... 85 
Figure 4-2: Affinity-matured nanobodies possess a combination of CDRs from the two lead 
clones. ........................................................................................................................................... 86 
Figure 4-3: Affinity-matured nanobodies potently neutralize SARS-CoV-2 pseudovirus and live 
virus............................................................................................................................................... 89 
Figure 4-4: Potent neutralizing nanobodies display high monovalent and bivalent affinities for 
the SARS-CoV-2 receptor-binding domain. ................................................................................. 91 
Figure 4-5: Affinity-matured nanobody recognizes an epitope in the receptor-binding domain 
that overlaps with epitopes recognized by ACE2 and other potent SARS-CoV-2 neutralizing 
nanobodies and antibodies. ........................................................................................................... 93 
Figure 4-6: Affinity-matured nanobodies display high stability and specificity. ......................... 96 
Figure 4-7: Nanobodies with nanomolar monovalent affinities can be generated via CDR-





Antibodies are an emerging class of biotherapeutics that are currently used for treating a 
myriad of diseases, including cancer, autoimmune disorders and viral infections. Their great 
success in the clinic is attributable to their many attractive properties, including their high affinity, 
drug-like biophysical properties (high specificity, stability, solubility), long circulation times in 
vivo, and amenability to protein engineering for further maturing their properties. Nevertheless, 
there are several outstanding challenges in their generation and engineering against complex 
targets that we have sought to address in this work. First, we have investigated in vitro methods 
for systematically generating antibodies with high conformational and sequence specificity against 
protein aggregates that form in neurodegenerative disorders such as Alzheimer’s and Parkinson’s 
disease. We have developed novel next-generation sequencing and flow cytometry library sorting 
methods to identify antibodies with high specificity for aggregates associated with Alzheimer’s 
disease (amyloid β and tau fibrils) and Parkinson’s disease (α-synuclein fibrils). Our anti-amyloid 
Aβ antibodies rival those of the FDA-approved drug, Aducanumab, in terms of their affinity (EC50 
values of ~1-10 nM) and conformational specificity while displaying much lower levels of off-
target binding.  We also developed a novel flow cytometry-based selection method by capturing 
amyloid aggregates on nanoparticles. Using this technique, we have successfully isolated 
conformational antibodies against tau and α-synuclein aggregates. Our tau antibodies display 
similar levels of affinity (EC50 values of ~0.5 nM) and conformational specificity as a leading 
clinical antibody, Zagotanemab, while displaying much lower levels of off-target binding. Our α-
synuclein antibody shows similar affinity (EC50 value of ~10-20 nM) and substantially higher 
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conformational specificity relative to a leading clinical-stage antibody, Cinpanemab. Moreover, 
we have also developed novel directed evolution methods for generating small antibodies 
(nanobodies) that potently neutralize SARS-CoV-2. Unexpectedly, we discovered that 
systematically swapping the binding loops between low affinity lead nanobodies results in 
unusually large increases in affinity and neutralization activity. We show that intentionally 
swapping nanobody binding loops during directed evolution is a powerful method for generating 
high-affinity nanobodies without the need for multiple rounds of affinity maturation. These 
approaches result in engineered antibodies and nanobodies that rival best-in-class molecules and 
hold great potential for advancing the field of antibody engineering to generate the next generation 
of safe and potent antibody drugs.  
 1 
 Introduction 
Antibodies belong to an important class of molecules used by an immune system to bind 
and neutralize foreign particles. They are ‘Y’ shaped glycoproteins which consists of four 
covalently linked polypeptide chains (Fig. 1A). They consist of two identical large chains known 
as ‘heavy chains’, each composed for 4 polypeptides domains namely: variable domain (VH), 
constant domains one (CH1), two (CH2) and three (CH3). They also consist of two identical small 
chains known as ‘light chain’, each composed of two polypeptide domains namely: variable light 
(VL) and constant light (CL) (Fig. 1, (1)). A monoclonal antibody is a bivalent molecule and is 
divided into three regions; it has two identical antigen binding regions (Fab; fragment antigen 
binding) composed of VH, CH1, VL and CL and crystallizable fragment (Fc, fragment crystallizable) 
 
 
Figure 1-1: Structure of an antibody 
(A) Illustration of a monoclonal antibody (IgG1, immunoglobulin 1) showing polypeptide chains (heavy and light chains) and 
different domains [variable heavy (VH), constant heavy 1,2,3 (CH1, CH2, CH3,), variable light (VL) and constant light (CL)]. (B) 
Antibody structure is divided into three regions, Fab (fragment antigen binding) and Fc (fragment crystallizable). 
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consisting of CH2-CH3 homo dimer (Fig. 1B, (1)). A full-length monoclonal antibody consists of 
12 domains with an average molecular weight of ~150 kDa or ~150 gm/mol.  
Although antibodies are natural molecules used by immune systems to fight against foreign 
particles, they can be re-programmed for several different applications including their use as re-
agents for detection, therapeutic and diagnostic applications. They have been used successfully as 
therapeutics for several diseases like cancers, autoimmunity diseases, inflammatory diseases, 
infectious diseases like SARS-CoV-2 and drug delivery. Many of the top selling drugs, including 
the best-selling drug (Humira or Adalimumab), are monoclonal antibodies. Currently, antibodies 
are the best class of bio-therapeutics with over 100 antibodies approved as drugs and another 20-
30 more under review (2).  
The grand success of antibodies in clinical trials can be attributed to many of their amazing 
properties including high affinity and exquisite specificity towards their target antigen (1,3). There 
are also some properties specific to their structure like effector function, re-formatting them as bi-
specific antibodies and antibody drug conjugates which make them very appealing for specific 
applications. Apart from these, they also have several drug-like properties which make them 
particular attractive like high stability and solubility, low off-target binding and toxicity, longer 
circulation times and ease of manufacturing, purification, storage, handling and shipping (1,3).  
Antibodies also have the flexibility of reformatting them into smaller fragments (Fig. 2) 
including nanobodies (Nb, single domain antibodies), single-chain variable fragments (scFv, two 
domain antibodies) or antigen binding fragments (Fab, four domain antibodies). These are 
attractive for special applications where larger size is a constraint or binding to cryptic and 
inaccessible sites or minimizing effector function. Several antibody fragments have also been 
approved for use as drugs (4,5). 
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Many of the amazing properties of an antibody or antibody fragment can be attributed to 
the variable domains: VH and VL. Each variable domain consists of three highly flexible and 
variable polypeptide loops known as complementarity determining regions (CDRs). These loops 
vary in amino acids chemistry and length giving rise to different binding properties and selectivity 
for antibodies. Since majority of the antigen binding characteristics of an antibody come from 
CDRs, the design of CDRs is particularly important and a lot of systematic research has been done 
for it .(1) 
 
 
Figure 1-2: Reformatting antibody into antibody fragments. 
Antibody can be reformatted into multiple fragments including nanobody (Nb, single domain), single chain variable fragment 
(scFv, two domains) and antigen binding fragment (Fab, four domains). 
 
In this work, we have mainly focused on designing CDRs for antibody fragments to achieve 
the desired set of binding properties. We have made antibody libraries, performed high throughput 
screening, isolation and engineering of antibodies. The design methods include rational design, 
grafting, error-prone PCR, directed and saturation mutagenesis. Depending on the target antigen 
and its properties and antibody scaffold some designs might work better compared to other so we 
have tried multiple strategies and reported the outcomes from the most promising ones.  
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We have used antibodies to target to proteins involved in multiple devastating 
neurodegenerative pathologies: tauopathies (6,7) and synucleinopathies (8). In neurodegenerative 
diseases or pathologies, the neurons lose their structure and functions over time which leads to 
their death. Diseases belonging to this class have a common mechanism: a healthy protein 
undergoes conformational change, starts aggregating and becomes toxic to cells. From a 
therapeutic or diagnostic view, it is very important to design molecules which would selectively 
bind to toxic fibrillary/aggregated conformers but not the benign monomer. In other words, the 
molecule of choice should have highest conformational specificity for fibrils over monomeric 
proteins. 
Tauopathies are associated with loss of memory and are characterized by the presence of 
intercellular tau neurofibrillary tangles (NFTs). Alzheimer’s disease is the most common 
tauopathy which is characterized by the presence of the two protein deposits: intracellular deposits 
of amyloid beta (Aβ) in addition to intercellular deposits of NFTs (9). Synucleinopathies are 
associated with loss of movements and Parkinson’s disease is the most common synucleinopathy 
characterized by the presence of α-synuclein fibrils. In this work, we have isolated antibodies with 
high affinity and high conformational specificity against Aβ, tau and α-synuclein aggregates. 
We have also successfully isolated high affinity and high neutralization potency antibodies 
against SARS-CoV-2 . This coronavirus is the cause of the current pandemic which has affected 
more than 150 countries with more than 130 million cases and 3 million deaths (10,11). 
In this work, we have successfully isolated and engineered antibodies with desired 
properties against Aβ, tau and α-synuclein amyloid aggregates and SARS-CoV-2 spike protein. 
Our antibodies rival or are better than best-in-class molecules including clinical and reagent 
antibodies and approved drugs. Our anti-amyloid Aβ antibodies rival approved drug, Aducanumab 
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in terms of affinity (~2-12 nM) and conformational specificity but show remarkably lower off-
target. We also developed a novel flow cytometry-based selection method by capturing amyloid 
aggregates on nanoparticles. Using this technique, we have successfully isolated conformational 
antibodies against tau and α-synuclein aggregates. Our tau antibodies display similar levels of 
affinity (~0.5 nM) and conformational specificity to clinical antibody Zagotanemab but 
considerably lower off-target binding. Our α-synuclein antibody show similar affinity (~20 nM) 
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  Rational Affinity Maturation Of Anti-Amyloid Antibodies With High 




Of the many human disorders facing our society today, neurodegenerative diseases such as 
Alzheimer’s and Parkinson’s diseases are arguably the most menacing and least treatable (12,13). 
These diseases – which are linked to the formation of toxic prefibrillar oligomers and amyloid 
fibrils – are particularly concerning because their frequency of occurrence is linked to age and, 
thus, the number of cases is expected to increase as life expectancy increases in the coming years 
due to significant advances in treating other human disorders such as cancer and heart disease.  
Conformational antibodies specific for different conformers of amyloid-forming proteins are 
important for detecting, disrupting and reversing toxic protein aggregation (14,15). Several 
previous reports have demonstrated creative methods for using immunization (15-23), 
autoantibody screening (16,24-33), directed evolution (34-37) and rational design methods (38-
43) for generating these antibodies. Despite this progress, there are several common problems 
associated with generating conformational antibodies against amyloid-forming proteins. First, the 
nature of amyloidogenic antigens is extremely complex and particularly unattractive for typical 
antibody selection methods due to their insolubility, heterogeneity in terms of size and 
conformation, hydrophobicity and multivalency. Second, the use of immunization to generate such 
antibodies is limited due to uncontrolled presentation of aggregated antigens to the immune system 
and immunodominant epitopes. Third, the use of conventional directed evolution methods such as 
yeast surface display is limited by the inability to use fluorescence-activated cell sorting due to the 
lack of soluble antigens.  
These and many other challenges typically result in antibodies that recognize protein 
aggregates with either conformational specificity [e.g., common fibril or oligomer structure 
(16,17,31)] or sequence specificity (e.g., linear peptide epitopes) but not both. Even in cases where 
antibodies with strict conformational and sequence specificity have been identified [e.g., 
(21,27,33,44,45)], these approaches typically require extensive secondary screening to identify 
such rare variants and are not readily extendable to generate conformational antibodies against 
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different sites in the same protein or other proteins in a systematic, efficient and predictable 
manner.  
Toward the goal of rational and efficient methods for generating high-quality antibodies with 
strict conformational and sequence-specificity, we have previously developed directed evolution 
methods for discovering lead antibodies with high conformational specificity (34). Our approach 
involves designing single-chain (scFv) antibody libraries with focused mutagenesis in the most 
important antibody complementarity-determining region (CDR) that typically governs antigen 
binding (heavy chain CDR3). We sampled combinations of mutations that are most commonly 
observed in natural antibodies based on tens of thousands of human antibody CDRs (46). From 
such libraries, we identified an attractive lead antibody (AF1) that recognizes amyloid fibrils of 
the A42 peptide with high conformational and sequence specificity (34). This antibody displays 
much weaker affinity for soluble A42 and extremely low levels of non-specific binding even at 
high antibody concentrations (100 nM). Interestingly, the low level of non-specific binding for 
AF1 is similar to that of several highly-specific, clinical-stage antibodies (47).  
Nevertheless, the affinity of AF1 for A42 fibrils is modest (EC50 of ~100 nM) and at least an 
order of magnitude weaker than other clinical-stage antibodies that target A42 aggregates. 
Therefore, we sought to affinity mature AF1 against A fibrils to increase affinity while 
maintaining strict conformational and sequence specificity as well as low levels of non-specific 
binding.  
To accomplish this, there are several challenges that must be addressed. The first and most 
significant challenge is that most mutations that increase the affinity of such conformational 
antibodies also increase specific interactions with soluble A (reduced conformational specificity) 
or non-specific interactions (reduced sequence specificity) or both. A second key challenge is that 
the multivalent nature of protein aggregates frustrates the selection of affinity-enhancing mutations 
due to avidity effects. A third challenge is the selection of antibody sites to mutate as well as sets 
of mutations to sample in order to maximize the likelihood of obtaining matured antibody variants 
with high specificity and low levels of non-specific interactions. Here we report an integrated 
approach for affinity maturing conformational antibodies specific for A fibrils and demonstrate 
that this approach results in antibody variants with favorable combinations of binding properties 
relative to A clinical-stage antibodies.   
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Results 
Antibody library design and identification of affinity-matured candidates– Our strategy for 
systematic affinity maturation of a lead A conformational antibody is summarized in Fig. 2-1. 
The first step in this process is to design an antibody library that preserves the antigen recognition 
activity of the lead antibody (AF1) while identifying sites in the CDRs for affinity maturation. 
Given that AF1 was generated by directed mutagenesis in heavy chain CDR3, we sought to identify 
sites in the other five CDRs for further mutagenesis. However, there are a large number of potential 
CDR sites to mutate (54 positions in the five CDRs) and a daunting number of theoretically 





Figure 2-1: Proposed method for systematically maturing the affinity and specificity of Aβ amyloid antibodies.  
A lead single-chain antibody fragment (scFv) specific for Aβ fibrils was mutated by targeting solvent-exposed and naturally 
diverse sites in three complementarity-determining regions (CDRs), including heavy chain CDR2 (H2) and light chain CDRs 1 
(L1) and 3 (L3). The library was displayed on yeast and sorted negatively against disaggregated Aβ and positively against 
aggregated Aβ using magnetic-activated cell sorting. The enriched libraries were subjected to deep sequencing, and clones with 
mutations predicted to be favorable were evaluated in terms of their affinities and conformational specificities.  
 
To limit the library design to a size that can be evaluated using standard display methods such 
as yeast surface display (~107-109 variants), we sought to identify the most attractive subset of 
CDR sites and subset of residues per site that met a number of design criteria. First, we reasoned 
that the most naturally diverse sites in human antibodies are the most attractive for mutagenesis 
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because they are most likely to be solvent exposed and positioned for productive engagement of 
the antigen while being least likely to adversely impact protein stability (46). We only considered 
CDR sites in which the most common residue on average in human antibodies, as judged by the 
AbYsis database of tens of thousands of human antibodies (48), was present at a frequency of 
<50%.  
Next, we prioritized the remaining CDR sites for mutagenesis with the goal of sampling 
combinations of four to six residues per site that included the wild-type residue and combinations 
of residues expected to lead to high antibody specificity in addition to high affinity. The lead AF1 
clone possessed five Asp and five Tyr residues in heavy chain CDR3, and we previously found 
that removal of either type of residue from this CDR reduced specificity and increased non-specific 
binding (49). Therefore, we identified sites in the other CDRs that were compatible with encoding 
the wild-type residue and at least one of these residues (Asp or Tyr) as well as other residues that 
are most common in human antibodies using degenerate codons (50). Third, we eliminated 
degenerate codons that included positively-charged residues (Arg, Lys and His) because we and 
others have shown that excessive positive charge in the antigen-binding site is linked to increased 
risk for non-specific interactions (51-57). We also eliminated degenerate codons that encoded stop 
codons and minimized the number of Cys-encoding codons while not completely eliminating 
them. The reason for not completely excluding Cys from the library design is because it is encoded 
by degenerate codons that include combinations of common CDR residues in human antibodies 
such as Gly, Tyr and Asp. Fourth, we selected degenerate codons that maximized the sum of the 
average frequencies of each residue in human antibodies to maximize coverage of the natural 
amino acid diversity of human antibodies. 
Our library design is shown in Fig. 2-2. We identified eleven sites for mutagenesis in three 
CDRs, namely five sites in heavy chain CDR2, four sites in light chain CDR 1, and two sites in 
light chain CDR3. At each site, the wild-type residue is boxed in red and the three to five mutations 
included in our designs are highlighted as bolded black font (Fig. 2A). At each site, the residues 
are listed in order of most common on average in human antibodies (top) to least common 
(bottom). For example, at position 52 in heavy chain CDR2, we sampled the wild-type residue 
(Tyr) along with five other residues that included Asp, two residues common in human antibodies 
at this position (Ser and Asn), and two residues that are less common but required because of the 
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constraints of degenerate codons. Using a similar strategy at the other ten CDR sites (Fig. 2-2B), 




Figure 2-2:  Design of AF1 antibody sub-library for affinity maturation that targets naturally diverse and solvent-exposed CDR 
sites with mutations that are common in human antibodies. 
(A) Sites in heavy (H2) and light (L1 and L3) chain CDRs were identified based on their solvent exposure, diversity in human 
antibodies, and compatibility with sets of mutations most commonly observed in human antibodies. The wild-type residues at 
each site (boxed in red) were included in the library, and the average frequency (%) of each residue observed at each site in 
human antibodies is color coded. Some of the most common residues in human antibodies were not sampled because they are 
incompatible with degenerate codons encoding the wild-type residue and other favorable residues. Residues in black and bold 
text were sampled at each site. (B) Summary of the designed antibody library at eleven CDR sites that includes the wild-type 
residue and three to five mutations that aim to sample combinations of residues most commonly observed in human antibodies. 




 Next, we generated the antibody library, displayed it on the surface of yeast as C-terminal 
Aga2 fusion proteins, and sorted the library against A42 fibrils immobilized on magnetic beads 
(Fig. 2-3). To maximize antibody specificity, we performed three negative selections per round of 
sorting to remove non-specific antibodies before performing positive selections against A fibrils. 
In rounds 1 and 2, we performed negative selections against disaggregated (immobilized) A to 
maximize conformational specificity. In rounds 3-5, we performed negative selections against islet 
amyloid polypeptide (IAPP) fibrils to maximize sequence specificity. After five rounds of sorting, 
we observed strong enrichment in terms of the percentage of yeast cells that bound to fibrillar A 
relative to control selections performed against disaggregated A (Fig. 2-3A). The ratio of the 
number of yeast cells retained against fibrillar A relative to that for disaggregated A was >100 




Figure 2-3: Summary of the results for sorting the yeast-displayed antibody library against Aβ fibrils. 
(A) The library was subjected to five rounds of selection against Aβ fibrils, and the percentage of retained cells was evaluated 
for both fibrillar and disaggregated Aβ. (B) The ratio of antibody-displaying yeast cells bound to fibrillar Aβ relative to 
disaggregated Aβ in each round of selection. In (A) and (B), 107 antibody-displaying yeast cells were used in rounds 2-5 of 
selection relative to 109 yeast cells in round 1.  
 
These promising sorting results led us to sequence the sorted antibody libraries before and after 
rounds 4 and 5 of selection to better understand mutations most strongly correlated with improved 
antibody binding (Fig. 2-4). We identified 7464 unique antibodies using deep sequencing and 
evaluated correlations between individual mutations or sets of mutations and enrichment ratios for 
antibody variants with such mutations. Therefore, we evaluated the Spearman correlation 
coefficients for all possible single and multiple sets of mutations by comparing the enrichment 
ratios for all antibody variants with either wild-type or mutant residues at these sites regardless of 
 16 
the residues at the other sites. While significant sets of mutations were identified when considering 
as few as one mutation and as many as nine mutations (the maximum we evaluated), we found that 
sets of five and six mutations led to the best combination of relatively large numbers of mutant 
(>10) and wild-type (>10) antibodies per set of mutations, high Spearman correlation values 
(>0.5) and high statistical significance (p-value<0.001). Moreover, we found that Spearman 
correlation coefficients were well correlated between rounds 4 and 5 of sorting, which 
demonstrates that the deep sequencing results are consistent between multiple rounds of sorting.  
For example, we evaluated a set of six mutations (T53A and Y56N in HCDR2, D28N, N30A 
and T31Y in LCDR1, and T94Y in LCDR3) by identifying all antibody variants that had these 
mutations (16 variants) or wild-type residues (16 variants) at these positions regardless of their 
residues at the other five mutated sites (Fig. 2-4A). We found that this set of mutations resulted in 
large, positive and highly significant Spearman correlation coefficients in both rounds 4 (=0.83 
and p-value of 8x10-8) and 5 (=0.85 and p-value of 2x10-9). We expected that antibody variants 




Figure 2-4: Identification of sets of affinity-enhancing mutations using deep sequencing. 
Antibody libraries were sequenced before and after sorts 4 and 5 against Aβ fibrils, and sets of six mutations were identified 
that were strongly correlated with increased enrichment relative to wild-type. (A) Correlation between the frequency of clones 
with a particular set of six mutations (T53A and Y56N in HCDR2, D28N, N30A and T31Y in LCDR1, and T94Y in LCDR3) 
and enrichment ratios for clones observed with the corresponding mutations. (B) Antibody variants with sets of six mutations 
that display strong correlation with improved enrichment for recognizing Aβ fibrils relative to wild-type (AF1). In (A), the lines 
(logistic regression curves) are guides to the eye. In (A) and (B), the Spearman correlation coefficients were evaluated using 
antibody variants with wild-type or mutant residues at the specified positions regardless of their residues at the other five mutated 
positions. There are two to four additional mutations not shown for each antibody variant because they are not one of the six 
mutations most correlated with improved enrichment ratios. Enrichment ratios were calculated as the ratios of the frequencies 
of each variant observed in the sequencing results for the fibril selections (output) divided by the corresponding values for the 
input frequencies. The color codes for the amino acids are described in Fig. 2. 
 
Several other sets of six mutations were observed that also displayed favorable Spearman 
correlations, and we selected antibody variants with these mutations for further analysis (Fig. 2-
4B). We also identified sets of five mutations with favorable Spearman correlation coefficients 
that correspond to these same antibody variants. The antibodies in Figs. 2-4B had a total of eight 
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to ten mutations, including the sets of five and six mutations most correlated with improved 
enrichment ratios, which is why the same antibodies appear in both figures.   
Selected antibody variants display increased affinity and high conformational specificity– We next 
generated the selected antibodies as Fc-fusion proteins and evaluated their affinities and 
conformational specificities. To critically evaluate our antibodies, we directly compared them to 
two clinical-stage antibodies specific for A, namely aducanumab and crenezumab. Aducanumab 
recognizes an N-terminal A epitope (residues 3-7), and selectively recognizes A fibrils and 
oligomers relative to disaggregated A In contrast, crenezumab recognizes a central A 
epitope (residues 13-24) and binds to both aggregated and disaggregated A. We grafted 
the variable domains of each clinical-stage antibody onto an IgG1 scaffold with a human Fc 
fragment, which resulted in differences in both antibody sequences outside of the variable regions, 
including in the CH1, hinge and Fc regions, between the antibodies tested in this study and the 
actual clinical-stage antibodies (e.g., crenezumab is an IgG4 antibody). Herein we refer to these 
antibodies as their common names despite these differences. The selected antibody clones and 
clinical-stage antibodies both expressed well (purification yield of >30 mg/L) and were isolated 
with high purity. 
 Given the primary goal of our work to affinity mature our lead A antibody (AF1), we 
evaluated the apparent affinity of the selected antibody variants relative to AF1 and the clinical-
stage antibody controls (Fig. 2-5A and 2-5B). As expected, we observe modest affinity for AF1 
binding to A fibrils (EC50 of 992 nM). Notably, we observed significant (order of magnitude) 
increases in affinity for all of the selected antibody variants, and the EC50 values (4-13 nM) were 
similar to crenezumab (91 nM) and modestly higher than aducanumab (30.2 nM).  
 Nevertheless, we have observed that it is relatively common to lose antibody conformational 
specificity during in vitro affinity maturation. Therefore, we next evaluated if the affinity-matured 
antibodies retained conformational specificity (Fig. 2-5C and 2-5D). To evaluate this, we pre-
incubated the antibodies (30 nM) with various concentrations of disaggregated A and then 
evaluated their fibril-binding activity. As expected, crenezumab displayed low conformational 
specificity and its binding to A fibrils was inhibited due to competition with disaggregated A. 
Conversely, aducanumab binding to fibrils was weakly inhibited by disaggregated A, which is 
consistent with its high conformational specificity (25). Notably, the binding of our affinity-
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matured clones to A fibrils was also weakly inhibited by disaggregated A(82-99% bound 
antibody at 1000 nM disaggregated A) and behaved similar to the parental antibody (AF1).  
 
 
Figure 2-5: Identified antibody variants display increased affinity and high conformational specificity for Aβ fibrils. 
(A) Concentration-dependent binding of selected antibody variants to immobilized Aβ fibrils. (B) Apparent affinity (EC50) of 
selected antibody variants for Aβ fibrils. (C) Binding analysis of antibodies (30 nM) pre-incubated with different concentrations 
of disaggregated Aβ prior to binding to immobilized Aβ fibrils. (D) Percentage of bound antibody to Aβ fibrils for antibodies 
(30 nM) pre-incubated with disaggregated Aβ (1000 nM). In (A-D), clinical-stage Aβ antibodies (aducanumab and crenezumab) 
were used for comparison, the results are average values, and the error bars are standard deviations (two independent repeats). 
 
 These encouraging results led us to evaluate conformational specificity of the selected 
antibodies using immunodot blots (Fig. 2-6). The parental antibody (AF1) displayed weak 
reactivity at 10 nM and required long exposure times (45 min) to detect signals for A fibrils. 
Conversely, the clinical-stage antibody controls and the affinity-matured variants at the same 
concentration developed signals rapidly, as evidenced by their results after a short-time (30 s) 
exposure (Fig. 2-6). Aducanumab and the selected affinity-matured variants (clones 93, 97 and 
101) displayed relatively high conformational specificity. Moreover, crenezumab displayed little 
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conformational specificity, as expected based on our results in Fig. 2-5. Longer exposures (45 min) 
for the clinical-stage and affinity-matured variants reveal additional binding to both fibrillar and 
disaggregated A. The nonlinear nature of the signals generated via immunoblots, especially at 





Figure 2-6: Immunoblot analysis of the conformational and sequence specificity of the affinity-matured Aβ antibodies. 
Fibrillar (F) Aβ, islet amyloid polypeptide (IAPP), α-synuclein (αSyn) and disaggregated (D) Aβ were immobilized on 
nitrocellulose membranes and probed with Aβ antibodies (10 nM in PBST with 1% milk), including aducanumab (Adu) and 
crenezumab (Cre). The blots were imaged after relatively short exposure times (30 s) except for AF1 (45 min exposure). A 
loading control blot was detected using colloidal silver stain. The experiments were repeated three times and a representative 
example is shown. 
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 Next, we evaluated the epitope recognized by our affinity-matured antibodies relative to 
aducanumab and crenezumab (Fig. 2-7). A fibrils that corresponded to full-length A42 or N-
terminal truncations were deposited on nitrocellulose blots and probed with various antibodies. 
AF1 and the affinity-matured clones strongly recognized A1-42 fibrils and weakly recognized 
fibrils without the first (A2-42) and second (A3-42) residues. Aducanumab also recognized 
similar A fibril variants, albeit more strongly, and very weakly recognized A4-42 fibrils. This 
finding is consistent with the N-terminal epitope of aducanumab reported previously (25,59). 
Conversely, crenezumab recognized fibrils of all of the peptide variants (including A4-42, A5-
42 and A11-42) given that its epitope is reported to be A residues 13-24 (59). These findings 
demonstrate that the affinity-matured antibodies recognize a conformational epitope involving A 




Figure 2-7: Conformational epitope analysis of Aβ antibodies.  
Aβ fibrils formed with different Aβ peptides, including several N-terminal truncations, were immobilized on nitrocellulose 
membranes and probed with different Aβ antibodies. Antibody binding was performed overnight at 10 nM in PBST with 1% 
milk (4 ˚C). Aducanumab (Adu) and crenezumab (Cre) were included as controls. The image was captured after a 3 min 
exposure. The experiments were performed three times and a representative image is shown.  
 
 We next evaluated if the affinity-matured antibodies recognize aggregated A formed in vivo 
(Fig. 2-8, 2-9). Therefore, we first evaluated the antibodies using immunodot blots of brain 
homogenates obtained from transgenic mice that overexpress humanized mutant amyloid 
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precursor protein and presenilin 1 (5xFAD) relative to control (wild-type) mice (Fig. 2-8). The 
parental antibody (AF1) displayed weak immunoreactivity with the 5xFAD samples, while the 
selected clones (93, 97 and 101) displayed strong and specific detection of 5xFAD samples from 
four mouse brains relative to those from four control mouse brains. Interestingly, aducanumab 
detected the 5xFAD samples and also weakly reacted with the wild-type samples, while 
crenezumab failed to detect either type of sample. At longer exposures, aducanumab and 
crenezumab displayed high background while the affinity-matured antibodies displayed strong and 
specific recognition of 5xFAD samples. Moreover, we confirmed these findings for two affinity-
matured antibodies (clones 93 and 97) using western blotting, and detected strong and specific 
signals for the 5xFAD samples for the PBS insoluble (Fig. 2-9) and PBS soluble fractions. For the 
latter samples, we did not observe antibody binding to low molecular weight A species for either 
the affinity-matured antibody (clone 97) or a sequence-specific antibody (NAB 228) that detects 
both low and high molecular weight A species (34). Finally, we also found that the affinity-
matured antibodies recognized A conformers in the human brain-tissue lysates of Alzheimer’s 
patients via immunodot blotting.   
 
 
Figure 2-8: Immunoblot analysis of transgenic (5xFAD) and wild-type mouse brain samples using Aβ antibodies. 
Brain samples (insoluble fraction) obtained from 5xFAD (22-24 months old) and wild-type mice were immobilized on 
nitrocellulose membranes and probed with Aβ antibodies (50 nM in TBST with 1% milk), including aducanumab (Adu) and 
crenezumab (Cre). The blots were imaged after a relatively short exposure (15 s). Ponceau S staining was used as a loading 
control (LC). The experiments were repeated three times and a representative example is shown.  
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 We also evaluated the ability of the affinity-matured antibodies to stain A aggregates in tissue 
sections of transgenic (5xFAD) mouse brains relative to wild-type mouse brains (Fig. 2-10). Clone 
97 selectively recognized plaques in the frontal cortex of 5xFAD mouse brains, while a sequence-
specific A antibody (NAB 228) recognized more diffuse material that surrounded the plaque 
cores, as observed by the lack of significant overlap of immunostaining for the two antibodies (Fig. 
2-10A). Aducanumab displayed similar staining of A plaques and also displayed little overlap in 
staining with the sequence-specific antibody (Fig. 2-10B). Notably, aducanumab displayed higher 
levels of non-specific binding to wild-type tissue than clone 97. We observed similar patterns of 
immunostaining for hippocampus (CA1) tissue samples using clone 97 (Fig. 2-10C) and 
aducanumab (Fig. 2-10D). Overall, these results demonstrate that our affinity-matured antibodies 
recognize A aggregates formed in vitro and in vivo with high affinity and conformational 




Figure 2-9: Western blot analysis of 5xFAD and wild-type mouse brain samples using affinity-matured Aβ antibodies. 
Brain samples (PBS insoluble fraction) isolated from 5xFAD (22-24 months old) and wild-type (WT) mice were processed 
(with or without boiling) via SDS-PAGE, transferred to nitrocellulose membranes, and probed with a subset of Aβ antibodies 
(100 nM in TBST with 1% milk). The blots were imaged after 6 min of exposure. Ponceau S staining was used as loading 




Figure 2-10: Immunofluorescence staining of 5xFAD and wild-type mouse brain sections using Aβ antibodies. 
(A-D) Mouse brain sections from the (A, B) frontal cortex and (C, D) hippocampus (CA1) were stained using conformational 
antibodies [clone 97 in (A) and (C) and aducanumab in (B) and (D)] at 200 nM, a sequence-specific Aβ antibody (NAB 228; 
recognizes Aβ 1-11) at 1:200x dilution, and DAPI. The 5xFAD mice were 8 months old. Slides were imaged using Leica SP5 
confocal microscope. The scale bars are 50 µm for the main images and 15 µm for the inset images. 
Affinity-maturated antibodies display favorable biophysical and specificity properties– One of the 
most common limitations of using in vitro antibody discovery and engineering methods is the 
generation of antibodies with suboptimal biophysical properties – such as low stabilities, 
solubilities and specificities – relative to antibodies generated by the immune system (47,60-62). 
Therefore, we next sought to evaluate the biophysical properties of our affinity-matured antibodies 
to determine if they maintained favorable specificities and stabilities (Fig. 2-11). First, we 
evaluated non-specific binding for our antibodies using a previously reported polyspecificity 
reagent (PSR) that is composed of soluble membrane proteins isolated from CHO cells (Fig. 2-
11A) (47,63). Antibody binding to this reagent is a strong indicator of the level of antibody 
specificity and the likelihood of abnormal pharmacokinetics (64). Encouragingly, our affinity-
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matured antibodies displayed extremely low levels of non-specific interactions that were similar 
to their parental antibody (AF1) and a control clinical-stage antibody with high specificity 
(elotuzumab) (47). Moreover, the matured antibodies were even more specific than crenezumab, 
which also displayed relatively low levels of non-specific binding. Interestingly, aducanumab 
displayed much higher levels of non-specific binding that were similar to the control clinical-stage 
antibodies with high levels of non-specific binding (emibetuzumab and duligotuzumab) (47). 
Although these results were performed using the affinity-matured antibodies after only one-step 
purification (Protein A) and the control clinical-stage antibodies after two-step purification 
(Protein A and size-exclusion chromatography), we obtained similar non-specific binding 




Figure 2-11: Biophysical characterization of Aβ antibodies. 
(A) Antibody non-specific binding to soluble membrane proteins. The soluble membrane proteins were biotinylated and their 
binding to immobilized antibodies was evaluated via flow cytometry. (B) Percentage of monomeric antibody evaluated via size-
exclusion chromatography. (C) Antibody melting temperature (midpoint of unfolding) evaluated using dynamic scanning 
fluorimetry. In (A-C), the values are averages and the error bars are standard deviations (three independent repeats). 
 
 We also evaluated the physical stabilities of our antibodies (Fig. 2-11B and 2-11C). Antibodies 
with poor stability often display aggregation at low pH during elution from Protein A columns 
(65-70). Therefore, we evaluated the percentage of monomeric antibody after Protein A 
purification for the affinity-matured antibodies relative to the control clinical-stage antibodies 
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(Figs. 2-11B and S9). Encouragingly, we observed that the affinity-matured antibodies displayed 
high levels of monomeric protein (>95%) that were similar to the clinical-stage antibodies. 
Moreover, we evaluated the melting temperatures of our single-chain antibodies (as scFv-Fc fusion 
proteins) relative to the clinical-stage IgGs (Figs. 2-11C and S10) to evaluate if affinity maturation 
reduced stability (3,71,72). Due to the lack of constant (CH1 and CL) domains, it is expected that 
the single-chain antibodies will have lower stabilities than the clinical-stage IgGs. Nevertheless, 
we find that the affinity-matured antibodies displayed high stabilities (Tm values of 64-69 ᵒC) that 
were comparable to the parental antibody (AF1, Tm of 69 ᵒC) and modestly lower than the clinical-
stage IgGs (74-79 ᵒC). In summary, our affinity-matured antibodies display a combination of 
biophysical properties that are favorable and unique in comparison to clinical-stage A antibodies.  
Additional affinity maturation does not compromise conformational and sequence specificity– We 
evaluated the feasibility of using our methods to further affinity mature one of the best antibody 
variants (clone 97) while maintaining high conformational specificity and low non-specific 
binding. Therefore, we designed and screened a sub-library for clone 97 with mutations in heavy 
chain CDR1 and light chain CDR2, as these two CDRs were the only ones not mutated during the 
initial round of discovery (heavy chain CDR3) and the first round of affinity maturation (heavy 




Figure 2-12: Additional affinity maturation results in an Aβ antibody variant (97A3) with improved affinity, high 
conformational specificity and low non-specific binding. 
(A) Concentration-dependent binding of clone 97A3 to Aβ fibrils relative to its parental antibody (clone 97) and aducanumab. 
(B) Binding analysis of antibodies (30 nM) pre-incubated with different concentrations of disaggregated Aβ prior to binding to 
immobilized Aβ fibrils. (C) Antibody non-specific binding to soluble membrane proteins. In (A) and (B), the experiments were 
performed as described in Figure 5. In (C), the experiments were performed as described in Figure 11.  
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 MACS selections against A42 fibrils yielded a single enriched antibody variant with five 
mutations in light chain CDR2 (97A3; Fig. 2-12). Notably, this clone displayed higher apparent 
affinity than the parental antibody (~6-fold improvement) and aducanumab (~3-fold improvement; 
Fig. 2-12A). Given that different batches of fibrils were used to perform the binding experiments 
in Figs. 5 and 12, the EC50 values for clone 97 (8±1 nM in Fig. 2-5 and 18±1 nM in Fig. 2-12) and 
aducanumab (3±1 nM in Fig. 5 and 10±2 nM in Fig. 2-12) were modestly different. Moreover, the 
affinity-matured antibody (97A3) displayed high conformational specificity similar to clone 97 
and aducanumab (Fig. 2-12B) and low non-specific binding that was similar to clone 97 and much 
lower than aducanumab (Fig. 2-12C). Moreover, 97A3 was mostly monomeric after one-step 
Protein A purification (>93%) and displayed high stability (Tm of 69±0.5 ᵒC) that was similar to 
the parental antibody (97% monomer and Tm of 68±2 ᵒC; Fig. S11). This demonstrates that our 
affinity maturation methods can be used to generate antibodies with superior affinity and levels of 
non-specific binding relative to aducanumab while maintaining high conformational specificity 
and thermal stability. 
Discussion 
 We have demonstrated a rational and systematic approach for affinity maturing conformational 
antibodies specific for insoluble polypeptide aggregates. Prior to this work, we were skeptical 
about the feasibility of this process due to the likelihood of strong avidity effects between 
multivalent yeast-displayed antibodies interacting with multivalent A aggregates immobilized on 
magnetic beads. In the case of soluble and monovalent antigens, it is much easier to select affinity-
matured antibodies using yeast surface display because of the reduced antigen-specific avidity 
effects and the ability to use FACS. However, in the case of insoluble aggregates, it is not possible 
to use FACS because of the particulate and insoluble nature of polypeptide aggregates.  
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 While any antibody engineering campaign has the potential to succeed if enough clones are 
screened, we found a surprisingly high level of success at identifying affinity-matured clones using 
our reported approach. For example, all 19 of the clones that were identified via our deep 
sequencing analysis displayed increased affinity during our primary screens performed with 
immunodot blots. Moreover, all of the 15 clones tested for conformational specificity displayed 
low levels of binding to disaggregated A in our competition experiments (Fig. 2-5C and 2-5D). 
Finally, all of the 15 clones tested for A fibril affinity displayed 8- to 20-fold improvements in 
their EC50 values compared to AF1 (Fig. 2-5A and 2-5B).  
 Given this higher-than-expected success rate, this raises the question of why this approach was 
successful and what are the most important aspects of this methodology to consider for future 
studies. One potentially relevant observation is related to how we identified sets of mutations most 
correlated with improved enrichment ratios using deep sequencing. This process assumes that the 
sets of mutations (e.g., sets of six mutations) govern the improved behavior and ignores the 
residues at the other randomized sites. It is logical that introducing these sets of mutations into the 
parental antibody – without introducing any mutations at the other sites – may improve antibody 
affinity. However, we found that this approach was much less robust, as <50% (7 out of 15) of the 
antibody mutants tested using this strategy showed increased affinity (as judged by immunoblots; 
data not shown). This suggests that mutated residues at sites not considered in a given mutational 
set (e.g., sites 1 and 2 when evaluating sets of mutations at sites 3-8) contribute to the overall 
binding activity and were important to our success in identifying affinity-matured variants.  
 We also suspect that our strategy for designing sub-libraries with particular types of mutations 
contributed to the success of selecting antibody variants with improved affinity while maintaining 
both conformational specificity for A aggregates and low levels of off-target binding. Given the 
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acidic nature of A42 (theoretical pI of 5.3), it is common in our experience to select positively-
charged mutations that increase antibody affinity due to attractive electrostatic interactions (51,72). 
However, over-enrichment in positively-charged residues in antibody CDRs is a key risk factor 
for off-target binding (49,53,54,56,57,73-76). Therefore, we eliminated positively-charged 
mutations from our library design. We speculate that this may have reduced (at least partially) the 
strong avidity effects due to reduction of relatively long-range (attractive) electrostatic interactions 
during library sorting. While positive charge is obviously not deleterious in all cases for specific 
and high-affinity binding, it may be that eliminating positively-charged mutations reduces non-
specific electrostatic interactions that frustrate selection of antibody clones with intrinsic increases 
in affinity due to avidity effects.  
 It is also notable that our parental (AF1) and affinity-matured antibodies display unusually low 
levels of non-specific binding. The origin of the high non-specific binding for A (aducanumab) 
and other non-A (emibetuzumab and duligotuzumab) clinical-stage antibodies relative to low 
non-specific binding for A (crenezumab) and non-A (elotuzumab) clinical-stage antibodies 
appears linked to the charge properties of the antibody variable regions (Table S1). The three 
antibodies with high non-specific binding have variable fragments (Fvs) that are either strongly 
positively-charged (+9.1 for aducanumab and +5.2 for emibetuzumab) or strongly negatively 
charged (-4.9 for duligotuzumab), as judged by their theoretical net charges at pH 7.4. In contrast, 
the antibodies with low non-specific binding have near neutrally charged Fvs (+0.2 for crenezumab 
and -0.9 for elotuzumab at pH 7.4). Moreover, AF1 and the affinity-matured clones with low levels 
of non-specific interactions have weakly positively-charged Fvs (+0.2 for AF1 and +1.2 to +2.2 
for the first-generation affinity-matured variants and +2.2 for the second-generation variant) that 
are intermediate to the antibodies with high levels of non-specific interactions. This suggests that 
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near neutrally (or weakly positively) charged Fvs may be optimal for high antibody specificity. 
This is consistent with the fact that clinical-stage antibodies with low levels of non-specific and 
self-interactions typically have Fvs with near neutral charges (1.5±2.5 at pH 7.4) (52), which 
overlaps with the observed Fv charges for the antibodies with high specificity in this study.  
 It is also notable that several A-specific antibodies have more positively-charged Fv regions 
(theoretical net charge at pH 7.4) than antibodies in this study with high specificity, including 
gantenerumab (+6.1), ponezumab (+4.2), BAN2401 (+2.3) and solanezumab (+3.2) in addition to 
aducanumab (+9.1; Table S1). The acidic nature of A, as noted above, is likely one reason for 
this bias toward positively-charged antigen-binding sites. However, in the case of A antibodies 
such as aducanumab that have abnormally positively-charged Fv regions, it is possible that these 
properties are linked to improved transport across the blood-brain barrier. A key step to adsorptive-
mediated transcytosis – which can be specific [receptor-mediated (77-80)] or non-specific 
[electrostatically mediated (81)] in nature – is antibody binding at the cell surface. Antibodies with 
positively-charged Fvs are known to interact with negatively-charged cell membranes and display 
enhanced cellular uptake (73,82,83). Moreover, antibodies that display high levels of non-specific 
interactions are linked to increased transcytosis in cell culture (80). Therefore, we speculate that 
the unique positively-charged properties of aducanumab variable regions – while potentially 
deleterious in terms of off-target binding – may be beneficial in promoting cellular internalization 
and transcytosis.  
 However, it is also notable that administration of A antibodies such as aducanumab and 
bapineuzumab have been linked to amyloid-related imaging abnormalities (ARIA) detected by 
magnetic resonance imaging (26,59,84-86). ARIA is associated with disruption of the blood-brain 
barrier (regional vasogenic edema). Interestingly, the effectiveness of aducanumab at reducing 
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amyloid in the brain is associated with increased frequency of brain edema or ARIA (26). This 
may suggest that the non-specific mechanism by which antibodies such as aducanumab enter the 
brain – which likely is enhanced by positively-charged Fv regions – results in a narrow therapeutic 
index (79). This also suggests that using bispecific antibodies that combine more specific A 
antibodies – such as those reported in this study – with antibodies that target receptors at the blood-
brain barrier (87-90) may enable the use of lower antibody doses, and be a safer and more effective 
strategy for targeting A aggregates in the brain.  
 It is also important to consider several other aspects of our methods and findings. First, we 
evaluated the apparent affinities (EC50 values) of the antibodies at relatively low antigen 
concentrations (1% biotinylated fibrils immobilized on beads at 1 µM), which we found to be 
important to differentiate between the parental (AF1) and affinity-matured variants. At higher 
antigen concentrations (10% biotinylated fibrils immobilized on beads at 6 µM), we observed 
smaller improvements for the affinity-matured variants (data not shown), which is likely due to 
avidity effects. Second, we evaluated the immunodot blots at different exposure times using X-ray 
film (Fig. 2-6) and found that the apparent conformational specificities were dependent on 
exposure time. Caution should be exercised when evaluating antibody conformational specificity 
using dot blots because the signal for aggregates in some cases can readily saturate while the signal 
for disaggregated peptide can continue to increase with exposure time, leading to potentially 
misleading results. Third, our deep sequencing analysis only scratched the surface of the many 
promising antibody candidates that could be evaluated in the future. Due to errors in our initial 
evaluation of the deep sequencing data, the reported antibody variants have favorable but not the 
most favorable sets of mutations and corresponding enrichment ratios. This suggests that there 
may be additional opportunities to generate even better antibodies using this approach in the future.  
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 Our findings suggest a number of additional future directions. First, our affinity maturation 
methodology could be readily applied to further increase the affinities of the reported A 
antibodies in this study. Second, we expect that this approach could be applied to evolve not only 
the affinity but also the conformational specificity of existing antibodies against diverse types of 
amyloidogenic aggregates. The ability to control antigen presentation to antibody sub-libraries 
enables the selection of variants with increased conformational specificity in addition to increased 
affinity. This is particularly important for aggregates such as prefibrillar oligomers that are 
challenging to isolate, stabilize and use as antigens for immunization. Moreover, even for 
conformational antibodies discovered by immunization, it is likely that additional affinity 
maturation would be beneficial for their use in diagnostic and therapeutic applications. Indeed, we 
are currently testing the generality of these methods for maturing the affinity and conformational 




Aβ solubilization and fibril preparation  
Aβ fibrils were prepared as described previously (34). Lyophilized Aβ1-42 (Anaspec, 
AS20276) and biotinylated Aβ1-42 (Anaspec, AS23526-05) peptide were dissolved in hexafluoro-
2-isopropanol (HFIP), aliquoted and stored at -80 ᵒC at 1 mg/mL (Aβ1-42) and 0.17 mg/mL 
(biotinylated Aβ1-42). For fibril preparation, aliquots were thawed and HFIP was evaporated 
overnight. Peptides were dissolved in 50 mM NaOH and ultracentrifuged at 221000xg at 4 ᵒC for 
1 h. The supernatant (typically 45 L) was collected, transferred to a new tube, and neutralized 
with nine times the volume (typically 405 L) of acidified PBS (PBS with 4.7 mM HCl). The 
peptide concentration was determined by measuring the absorbance at 280 nm.  
Unlabeled fibrils were assembled at 37 ᵒC for at least 3 d without agitation by further diluting 
the soluble peptide in PBS to a final concentration of 12.5 µM along with the addition of 10% 
fibril seeds (1.25 µM of preformed fibrils). Biotinylated fibrils were assembled in similar manner 
except that the assemblies were doped with 1 or 10% biotinylated Aβ monomer (final 
concentration of Aβ monomer was 12.5 µM). After at least 3 d, the assemblies were 
ultracentrifuged at 221000xg for 1 h (4 ᵒC). The supernatant was discarded and the fibril pellet 
was re-suspended in fresh PBS (typically ~100 µL for unlabeled fibrils). For biotinylated fibrils, 
the pellet was resuspended in the same initial volume to achieve a nominal fibril concentration of 
12.5 µM. Unlabeled fibrils were briefly sonicated for 30 s (three cycles of 10 s on and 30 s off) on 
ice and their concentration was determined by the BCA assay. Biotinylated fibrils were sonicated 
for 2 min (12 cycles of 10 s on, 30 s off) on ice before incubating them with Streptavidin 
Dynabeads (Invitrogen, A11047). For fibril bead preparation for sorting, 10% biotinylated fibrils 
(6 µM) were mixed with 107 beads in a final volume of 400 L in PBSB (PBS with 1 mg/mL 
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BSA). For fibril bead preparation for antibody analysis, 1% biotinylated fibrils (1 µM) were mixed 
with 107 beads in a final volume of 400 L in PBSB. 
Antibody library generation 
Antibody library genes (theoretical diversity of 1.1x108) were prepared by PCR. Three 
degenerate oligos were designed with diversity in LCDR1, LCDR3 and HCDR2. Four individual 
PCRs were performed for the AF1 scFv gene using the yeast surface display plasmid (34) as a 
template, three of which used degenerate primers. Overlap PCR was then performed to combine 
DNA fragments with terminal primers. The PCR product was purified via a 1% agarose gel 
followed by gel extraction (Qiagen, 28706). The wild-type AF1 scFv plasmid was double digested 
with NheI-HF (New England Biolabs, R3131L) and XhoI (New England Biolabs, R1046L), 
treated with alkaline phosphatase (New England Biolabs, M0525L), and purified via a 1% agarose 
gel. The digested backbone was cut and purified with a gel extraction kit. The scFv gene and 
digested backbone were ligated by homologous recombination in the EBY100 yeast strain 
(Saccharomyces cerevisiae) via electroporation, as described earlier (34,91). The total number of 
transformants obtained was ~109.  
For clone 97 affinity maturation, a library was constructed by diversifying five positions in 
light chain CDR2 and five positions in heavy chain CDR1 using NNK codons. The antibody genes 
were prepared by overlap extension PCR. The plasmid backbone was digested with NheI-HF and 
XhoI, treated with alkaline phosphatase, and purified by 1% agarose gel. The scFv antibody library 
genes were ligated by homologous recombination in the yeast strain EBY100 via electroporation 
as described above. The total number transformants obtained was ~5x108.  
Yeast surface display and sorting  
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Five rounds of magnetic-activated cell sorting (MACS) were performed against Aβ fibrils 
(10% biotinylated fibrils) immobilized on streptavidin beads. For round 1, yeast cells (109) 
expressing antibodies were sorted first using negative selections (three times) against 
disaggregated (biotinylated) Aβ immobilized on streptavidin beads (107 beads per round) in PBSB, 
as described previously (34). Next, the remaining yeast cells after negative selections were sorted 
against 107 beads coated with Aβ fibrils in PBSB supplemented with 1% milk for 3 h (room 
temperature). The yeast cells bound to fibril-coated beads were collected by magnetic separation, 
washed, and grown in low pH SD-CAA media (20 g/L of dextrose, 6.7 g/L of yeast nitrogen base 
without amino acids, 5 g/L of casamino acids, 16.75 g/L of sodium citrate trihydrate, 4 g/L citric 
acid). Dilutions were plated to estimate the number of cells collected for the selections against Aβ 
fibrils. For round 2, the sorting was performed in similar way except with a reduced number of 
yeast cells (107 cells).  
For rounds 3, 4 and 5, the sorting was performed in similar way as round 2 except that the 
negative selections were performed against IAPP fibrils (10% biotinylated IAPP fibrils 
immobilized at a peptide concentration of 6 M). IAPP and biotinylated IAPP peptide were 
dissolved in HFIP at 1 mg/mL, aliquoted and frozen at -80 ᵒC. Next, the peptides were thawed 
followed by snap freezing in liquid nitrogen and lyophilization. The lyophilized peptide was 
dissolved at pH 7.4 in 20 mM Tris (typically 150 µL) and centrifuged at 21000xg for 10 min to 
remove aggregates. The supernatant (typically 145 µL) was then transferred to a new tube. The 
peptide concentration was determined by measuring the absorbance at 280 nm. Fibrils were 
assembled at 32 µM (10% biotinylated peptide) at 37 ᵒC and 300 RPM for 3-4 d. Post assembly, 
fibrils were purified by ultracentrifugation at 221000xg for 1 h at 4 ᵒC. The fibril pellet was re-
suspended to the same final volume to achieve fibrils at 32 µM. For bead preparation, fibrils were 
 41 
sonicated for 2 min (10 s on, 30 s off) on ice followed by mixing with streptavidin beads (6 µM 
fibrils with 107 beads in a final volume of 400 µL) 
For clone 97 affinity maturation, MACS was performed as described above. For round 1, 109 
yeast cells expressing antibodies were incubated with 107 beads coated with Aβ fibrils (1% 
biotinylated fibrils were immobilized at 1 µM A42) at room temperature for 3 h in PBSB with 
1% milk. Yeast cells bound to fibril-coated beads were collected via a magnet, washed once with 
ice-cold PBSB, and grown in SDCAA media. For rounds 2 and 3, sorting was performed in a 
similar way except with 107 cells. In round 4, a negative selection was performed against 
biotinylated and disaggregated Aβ monomer (1000 nM) via FACS. Antibody display was detected 
using mouse anti-myc antibody (Cell Signaling, 2276S) at 1/1000x dilution followed by secondary 
staining with goat anti-mouse IgG (H+L) AF488 (Invitrogen, A11001) at 200x dilution. 
Disaggregated Aβ binding was detected using streptavidin AF647 (Invitrogen, S32357) at 1000x 
dilution. Yeast cells displaying antibody but not binding to disaggregated Aβ were collected and 
grown in SDCAA media. For rounds, 5, 6, 7 and 8, MACS was performed as described above with 
107 cells and 107 beads. In rounds 6, 7 and 8, after incubating yeast with fibril-coated beads, yeast 
bound to such beads were washed (3x for 20 min per wash with end-over-end mixing) with PBSB 
supplemented with 0.05% Tween 20 to select for antibodies with increased affinity and potentially 
with lower off-rates. 
Deep sequencing and data analysis 
Yeast plasmids containing scFv genes were extracted after regrowing the sorted antibody 
libraries from rounds 2-5 using a Zymoprep Yeast Plasmid Miniprep II Kit (Zymo Research, 
D2004). PCR was used to amplify a portion of the scFv gene containing LCDR1, LCDR3, and 
HCDR2, and to add Illumina adapter regions as well as DNA barcodes. These PCR products were 
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run on 1% agarose gels and purified using a QIAquick Gel Extraction Kit (Qiagen, 28704). A 
second PCR was performed with 2 µL of the purified products using primers that anneal to the 
Illumina adapter regions. This product was also purified via a gel extraction kit. The samples were 
sequenced using Illumina MiSeq with 300 bp paired-end sequencing reactions.  
To analyze the paired-end output .fastq files, the two .fastq files corresponding to each sample 
were merged into one .fastq file using BBMerge with the qtrim parameter set to 15 (92). The 
resulting file was converted to a .fasta file and each line was analyzed. The lines containing a 
sequence were checked to ensure it was the correct length (540 bp) and that there were not bases 
called as ‘N.’ If so, it was translated using BioPython (93). If the resulting translation did not 
contain stop codons and started with the correct amino acid (T), it was further analyzed. Otherwise, 
the reverse complement of the sequence was translated and checked for starting amino acid and 
stop codons. Next, the eleven residues with potential mutations in the sequences were identified 
and added to a dictionary if they were previously unobserved or increased their count of 
observation. This process was repeated for every sample and the results were recorded in a .csv 
file. 
To select clones for experimental evaluation, mutational analysis was performed to identify 
sets of mutations most strongly correlated with improved antibody binding. For example, for a 
given set of potential mutations (e.g., D61G in HCDR2 and D28N, N30Y and A34T in LCDR1), 
clones were collected that contain those mutations (potentially among others) as well as all the 
clones with wild-type residues in those positions (irrespective of other mutations). Next, the 
Spearman correlation coefficients were calculated for the correlations between the enrichment 
ratios of the identified clones (x-axis) and the frequencies of mutations (y-axis). Mutational 
analysis was conducted for one to nine mutations, and at least ten clones were required in each of 
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the mutant and wild-type sets. Moreover, the Spearman correlation coefficients were required to 
be statistically significant (p-value <0.05). 
Mammalian plasmid cloning, expression and purification 
Antibody sequences selected from deep sequencing analysis were ordered as separate VL and 
VH geneblocks. The geneblocks were combined by overlap PCR with primers containing NheI 
(forward primer) and HindIII (reverse primer) restriction sites. The PCR products were run on 1% 
agarose gels and purified via a Qiagen gel extraction kit. The purified DNA fragments were then 
double digested by NheI-HF (New England Biolabs, R3131L) and HindIII-HF (New England 
Biolabs, R3104L) and further purified using a PCR clean-up kit (Qiagen, 28104). HEK293-6E 
mammalian expression plasmids were double digested with NheI-HF and HindIII-HF followed by 
alkaline phosphatase treatment. The digested backbone was then gel purified using a 1% agarose 
gel. DNA inserts and plasmid backbones were ligated by T4 DNA ligase (New England Biolabs, 
M0202L), and the ligation mixtures were transformed into competent DH5α cells and plated on 
LB agar plates supplemented with 100 µg/mL ampicillin. Single colonies were picked, grown in 
LB supplemented with ampicillin, mini-prepped (Qiagen, 27106), and sequence confirmed.   
For antibody expression, plasmids (15 µg) were mixed with PEI (45 µg) in F17 media 
(Invitrogen, A1383502) and incubated at room temperature for 10-20 min after vortexing briefly. 
The resulting mixture was then added to cells growing in F17 media supplemented with L-
glutamine (Gibco, 25030081), Kolliphor (Fisher, NC0917244) and antibiotic G418 (Gibco, 
10131035). Yeastolate (BD Sciences, 292804) was added at 20% w/v after 24-48 h. The expression 
was continued for 4-5 d, and media was collected by centrifuging cells at 3500xg for 40 min. The 
media was transferred to a new tube and 1 mL of Protein A resin (Pierce, 20333) was added. Media 
and beads were rocked gently overnight at 4 ᵒC. Beads were collected by passing media through a 
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filter column (Thermo Fisher Scientific, 89898) under vacuum. Beads were washed with 50-100 
mL of PBS and protein was eluted from the beads in 0.1 M glycine (pH 3). Protein was then buffer 
exchanged into 20 mM acetate (pH 5) using Zeba desalting column (Thermo Fisher Scientific, 
89894), passed through 0.2 µm filters (EMD Millipore, SLGV004SL), aliquoted, and stored at -
80 ᵒC. Protein concentrations were determined by measuring the absorbance at 280 nm, and purity 
was evaluated by SDS-PAGE (Invitrogen, WG1203BOX). 
Analytical size-exclusion chromatography 
The purity of antibodies after the first purification step (Protein A) was also evaluated using 
size-exclusion chromatography (SEC). A Shimadzu Prominence HPLC System was used that was 
outfitted with a LC-20AT pump, SIL-20AC autosampler and FRC-10A fraction collector. 
Antibodies in 20 mM acetate (pH 5) were buffer exchanged into PBS (pH 7.4). For analytical SEC, 
100 µL of antibodies (diluted to 0.1 mg/mL) were loaded onto a SEC column (Superdex 200 
Increase 10/300 GL column; GE, 28990944) and analyzed at 0.75 mL/min using a PBS running 
buffer supplemented with 200 mM arginine (pH 7.4). Absorbance was monitored at 220 and 280 
nm, and the 280 nm signal was primarily used for analysis. The percentage of antibody monomer 
was evaluated by analyzing the area under the monomeric peak (excluding times before 7 min and 
after 22 min). In some cases, the antibodies were purified using SEC after Protein A purification. 
In those cases, the peak times for fraction collection were chosen based on the analytical runs. 
Antibody fractions were collected, buffer exchanged into PBS (pH 7.4), filtered, aliquoted and 
stored at -80 ᵒC.  
Antibody binding analysis 
For affinity analysis, the binding of antibodies [including clinical-stage antibodies whose 
sequences were obtained from the Therapeutic Antibody (TABS) database] to Aβ fibrils was 
 45 
evaluated using streptavidin dynabeads and flow cytometry. Beads were immobilized with 1% 
biotinylated fibrils as described above. The fibril-coated beads were washed twice with PBSB and 
then blocked with 10% milk in PBS at room temperature for 1 h with end-over-end mixing. 
Afterward, the beads were washed 2x with PBSB.  
Antibodies were thawed and centrifuged at 21000xg for 5 min to remove aggregates. The 
supernatant was transferred to a new tube and the antibody concentration was determined by 
measuring absorbance at 280 nm. Antibody dilutions were made in PBSB. Fibril-coated beads 
(1.25x105 beads per antibody concentration) were incubated with antibodies in 96-well plates 
(Greiner, 650261) in 1% milk for 3 h at 25 ᵒC (300 RPM). Next, the plates were centrifuged at 
3500 RPM for 5 min, the supernatants were discarded, and the beads were washed once with ice-
cold PBSB. After washing, the plates were spun down again and the beads with resuspended with 
300x diluted goat anti-human Fc AF647 (Jackson Immunoresearch, 109-605-098) on ice for 4-5 
min. Beads were then washed once more with ice-cold PBSB and analyzed via flow cytometry 
using a BioRad ZE5 Analyzer. For control beads, blank streptavidin beads were also blocked with 
10% milk in PBS and treated in the same way as the fibril-coated beads. Two independent repeats 
were performed with different batches of beads coated with Aβ fibrils.  
For antibody conformational specificity analysis, the experiments were performed in the same 
way as described above except that the antibodies were pre-incubated with disaggregated (non-
biotinylated) Aβ. Antibody binding analysis was performed in 1% milk at a fixed antibody 
concentration (30 nM) and a range of disaggregated Aβ concentrations. The antibody binding 
results were normalized to the average value obtained without disaggregated Aβ. Two independent 
repeats were performed with different batches of beads coated with Aβ fibrils.  
Antibody epitope analysis 
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Fibrils were also assembled using Aβ peptides with N-terminal deletions including A2-42 
(Bachem, 40306028.0500), A3-42 (Bachem, 4090137.0500), A4-42 (Bachem, 4090138.0500), 
A5-42 (Bachem, 4041241.0500) and A11-42 (Anaspec, 63317) in addition to Aβ1-42, and 
purified using ultracentrifugation. Fibrils were then spotted on nitrocellulose membranes at equal 
Thioflavin T florescence. Membranes were blocked with 5% milk in PBS at room temperature for 
1 h followed by 3x washing with PBST (PBS with 0.1% Tween 20). Membranes were then 
incubated with A  antibodies at 10 nM (1% milk) in PBST at room temperature for 2-3 h. 
Following primary incubation, membranes were washed 3x with PBST followed by incubation 
with goat anti-human Fc IgG HRP (1/5000x dilution, Invitrogen, A18817) in PBST at room 
temperature (1 h). Following secondary incubation, the blots were washed 3x with PBST, 
developed with ECL (Pierce, 32109) and imaged with a Bio-Rad imager.   
Polyspecificity analysis 
The polyspecificity reagent (PSR) was prepared as previously described (63). CHO cells (109, 
Gibco, A29133) were pelleted, the cell pellets were washed separately with PBSB and Buffer B 
(50 mM HEPES, 0.15 M NaCl, 2 mM CaCl2, 5 mM KCl, 5 mM MgCl2, 10% Glycerol, pH 7.2), 
and then pelleted again. The pellets were resuspended in 5 mL of Buffer B supplemented with a 
protease inhibitor (Sigma Aldrich, 4693159001). Next, the resuspended cells were homogenized 
for 90 s (three cycles of 30 s) followed by sonication for 90 s (three cycles of 30 s).  The cell 
suspension was then spun down at 40000xg for 1 h and the supernatant was discarded.   
The pellet, comprising the enriched membrane fraction, was resuspended in Buffer B with a 
Dounce homogenizer for 30 strokes.  The protein concentration was determined using a detergent 
compatible protein assay kit (BioRad, 5000116).  The enriched membrane fraction was diluted to 
a theoretical concentration of 1 mg/mL in solubilization buffer (pH 7.2), the latter of which 
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contained  50 mM HEPES, 0.15 M NaCl, 2 mM CaCl2, 5 mM KCl, 5 mM MgCl2, 1% n-dodecyl-
-D-maltopyranoside (Sigma Aldrich, D4641), and a protease inhibitor (Sigma Aldrich, 
11873580001). The solution was then mixed overnight (end-over-end) at 4 ᵒC.  The soluble 
membrane protein fraction was centrifuged at 40000xg for 1 h and the supernatant was collected. 
The final concentration of supernatant was ~0.8-0.9 mg/mL.  
Sulfo-NHS-LC-biotin (Thermo Fisher, PI21335) was dissolved in distilled water at ~11.5 
mg/mL. The stock solution of Sulfo-NHS-LC-biotin (150 L) and the PSR reagent (4.5 mL at 0.8-
0.9 mg/mL) were mixed via end-over-end mixing at room temperature (45 min). The reaction was 
quenched (10 L of 1.5 M hydroxylamine at pH 7.2), and biotinylated PSR was aliquoted and 
stored at -80 ᵒC. 
Protein A magnetic beads (Invitrogen, 88846) were washed twice and incubated with 
antibodies in 96-well plates (VWR, 650261) overnight at 4 ᵒC. The antibodies were purified either 
via one-step (Protein A) or two-step (Protein A followed by SEC) purification methods. Next, the 
antibody- coated beads were washed by centrifuging the 96-well plates at 3500xg for 4 min and 
washed twice with PBSB. Afterward, the beads were resuspended with a 10x diluted solution of 
biotinylated PSR and incubated on ice for 20 min. Beads were washed once with PBSB and 
incubated with 1000x diluted solution of streptavidin AF-647 (Invitrogen, S32357) and 1000x 
diluted solution of goat anti-human Fc F(ab’)2 AF-488 (Invitrogen, H10120) on ice (4 min). Bead 
were washed once, resuspended in PBSB, and analyzed via flow cytometry. The antibody binding 
steps were performed in PBSB, and three independent repeats were performed. The control 
antibodies used were the variable regions of crenezumab, elotuzumab, duligotuzumab and 
emibetuzumab grafted onto a common IgG1 framework, which results in differences in the 
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antibodies we have evaluated and the actual clinical-stage drugs. The control antibodies were two-
step purified (Protein A and SEC).  
Immunoblotting analysis of synthetic Aβ peptides 
For immunoblots using synthetic A peptides, disaggregated Aβ and unlabeled Aβ fibrils were 
prepared as discussed above. Disaggregated Aβ, and fibrils of Aβ, IAPP and α-synuclein were 
spotted on nitrocellulose membranes. Membranes were allowed to dry for at least 1 h at room 
temperature before use. Membranes were blocked with 5% milk in PBS for 1 h at room 
temperature. Afterward, the membranes were washed 3x using PBST (PBS with 0.1% v/v Tween 
20) with rocking (5 min). Antibodies were thawed, centrifuged, and their concentrations were 
determined via absorbance measurements at 280 nm. Antibody binding was performed at 10 nM 
in PBST with 1% milk at room temperature (3 h). Next, the membranes were washed 3x with 
PBST and incubated with a 7500x diluted solution of goat anti-human Fc HRP (Invitrogen, 
A18817) at room temperature (1 h). Following secondary incubation, the blots were washed 3x 
with PBST and developed with ECL (Pierce, 32109). The signals were evaluated using X-Ray film 
(Thermo Scientific, 34090) and the films were developed. Three independent repeats were 
performed for all experiments. 
Mouse models 
This study was conducted in a facility approved by the American Association for the 
Accreditation of Laboratory Animal Care, and all experiments were performed in accordance with 
the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved 
by the Institutional Animal Care and Use Committee of the University of Michigan. Mice were 
housed at the University of Michigan animal care facility and maintained according to U.S. 
Department of Agriculture standards (12 h light/dark cycle with food and water available ad 
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libitum). 5xFAD mice (B6.Cg_Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax; The 
Jackson Laboratory MMRRC stock #034848) expressing human amyloid precursor protein (APP) 
and presenilin-1 (PSEN1) with five AD mutations: the Swedish (K670N/M671L), Florida 
(I716V), and London (V717I) APP mutations and the M146L and L286V PSEN1 mutations and 
non-transgenic littermates (courtesy of Geoffrey Murphy, University of Michigan) were 
euthanized at 8 months (for immunofluorescence analysis) and 22-24 months (for immunoblots 
and western blots) for brain collection. 
Tissue harvesting  
Animals were deeply anesthetized with isofluorane and perfused transcardially with 1x PBS. 
Brains were divided sagittally. One half was immediately placed on dry ice and stored at -80 °C 
for biochemical studies while the other half was fixed in 4% paraformaldehyde at 4 °C for 24 h, 
and cryoprotected in 10% and 30% sucrose solutions in 1xPBS at 4 °C until saturated. Fixed 
hemispheres were snap frozen in OCT medium and sectioned at 12 μm sagittally using a cryostat 
and sections were stored at -20 °C for immunofluorescence. 
Immunoblotting and western blotting analysis of mouse brain samples 
The 5xFAD and non-transgenic littermate forebrain samples were homogenized in PBS with 
a protease inhibitor cocktail (Sigma Aldrich, 11873580001) using a 1:3 dilution of tissue: PBS 
(w/v). Samples were centrifuged at 9300xg for 10 min at 4 °C. Supernatants (soluble fraction) 
were snap frozen and stored at -80℃ for Western blot analysis. Pellets were resuspended in PBS 
with protease inhibitor cocktail (Roche, 11836170001), centrifuged at 9300xg for 10 min (4 °C), 
and supernatants were discarded. The pellet was resuspended in radioimmunoprecipitation assay 
(RIPA) buffer with protease inhibitor, vortexed (1 min), and incubated at room temperature (1 h). 
Samples were sonicated (water bath sonicator) for 5 min and centrifuged for 30 min (16000xg at 
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4 ºC). RIPA (PBS soluble and insoluble) fractions of brain extracts (7 µg of total protein) were 
spotted directly onto nitrocellulose membranes and allowed to dry (1 h). Control dot blots (loading 
controls) were stained with Ponceau S (5 min) and washed 3x with distilled water. The other dot 
blots were blocked with 10% nonfat dry milk in Tris Buffered Saline with 0.1% Tween 20 (TBST) 
buffer at room temperature (1 h). Each dot blot was then incubated with antibodies at 50 nM (1% 
nonfat dry milk in TBST) overnight at 4 o C. Next, the blots were washed with TBST and incubated 
with a 5000x diluted solution of HRP-conjugated goat anti-human IgG at room temperature for 1 
h. Afterward, the blots were washed with TBST and developed using Ecobright Nano HRP 
Substrate (Innovative Solutions) and visualized with the Genesys G:Box imaging system 
(Syngene). Three independent repeats were performed. 
For western blotting, 50 µg of total protein was loaded on precast NuPAGE 4-12% Bis-Tris 
gels (Invitrogen, WG1402A). Gels were subsequently transferred onto nitrocellulose membranes 
and first stained with Ponceau S and washed 3x with distilled water. After imaging, membranes 
were destained for 1 min with 0.1 M NaOH and washed 3x with distilled water. Next, membranes 
were blocked for 1 h at room temperature with 10% nonfat dry milk in TBST buffer. Membranes 
were probed overnight at 4℃ with aducanumab (Adu) and NAB 228 (Sigma-Aldrich, A8354; 
recognizes A1-11) at 100 nM in TBST with 1% milk or 100 nM antibody (clone 93 or 97) in 1% 
nonfat dry milk in TBST. HRP-conjugated goat anti-human/mouse IgG (5000x dilution) HRP was 
used for detection. Ecobright Nano HRP Substrate (Innovative Solutions) was used to visualize 
bands with the Genesys G:Box imaging system (Syngene). Three independent repeats were 
performed.  
Human disease brain tissue 
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Frozen brain tissue from the anterior cingulate was obtained from subjects with MSA, and 
age-matched control subjects from the Michigan Brain Bank (University of Michigan, Ann 
Arbor, MI, USA). Brain tissue was collected with the informed consent of the patients. Protocols 
were approved by the Institutional Review Board of the University of Michigan and abide by the 
Declaration of Helsinki principles. Samples were examined at autopsy by neuropathologists for 
diagnosis.  
Processing of human brain tissues 
Lysis buffer (600 L; 50 mM Na phosphate, pH 7.4, 150 mM NaCl, 2 mM EGTA, 2 mM 
EDTA, PhosSTOP (Sigma-Aldrich; 4906845001), cOmplete EDTA-free Protease Inhibitor 
Cocktail mini (Sigma-Aldrich; 11836170001), 6 μL/ml saturated phenylmethylsulfonyl fluoride 
(PMSF), and 10 mM Na azide) were added to 0.3 g of hippocampal tissue from individuals 
diagnosed with AD and age-matched controls negative for Aβ, α-synuclein, and tau pathology. 
Next, tissue samples were homogenized in safe-lock tubes containing 4 zirconium beads per tube 
for 1 min (speed 4) followed by cooling on ice for 5 min (Nova Advance homogenizer, Next 
Advance). Homogenization was repeated three more times. For additional homogenization, 
samples were passaged five times through a 25G needle, followed by centrifugation at 1,000xg for 
10 min. After resuspension with 150 μL lysis buffer, pellets were passaged five times through a 
25G needle syringe. Then samples were sonicated (PIP 50, DF 10%, and CPB 200) for 100 cycles 
(1 s ON and 1 s OFF) in M220 Focused-ultrasonicator (Covaris). To digest RNA/DNA, 1 μL 
benzonase (Sigma; E1014) was added to 50 μL sample (1:50 ratio) supplemented with 2 mM 
MgCl2 (final concentration). After incubation for 30 min at room temperature, equal volumes of 
benzonase-treated samples and 1% sarkosyl were incubated for 30 min at 4 ℃. Following 
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centrifugation at 18,000xg, the total protein concentrations of the pellets was determined by BCA 
and used for the dot blots. 
Immunofluorescence analysis of mouse brain samples 
Fixed brain sections were post-fixed for 10 min in methanol at 4 ℃. Sections were washed in 
1x PBS three times for 10 min and subjected to heat-induced antigen retrieval in 10 mM citrate 
buffer (pH 6). Sections were washed in 1x PBS two times for 5 min and permeabilized with 0.5% 
Triton-X 100, washed for 10 min in 1xPBS, and blocked using the Mouse on Mouse (M.O.M.) 
Mouse IgG Blocking Reagent (M.O.M. Immunodetection Kit, Vector, BMK-2202) for 1 h. 
Sections were washed 2x for 2 min in 1x PBS and incubated for 5 min in M.O.M. diluent. Sections 
were then incubated with Aβ antibodies aducanumab or 97 (200 nM) and NAB 228 (200x dilution) 
in M.O.M. diluent overnight at 4 ℃. The following day, sections were washed in 1x PBS three 
times for 10 min each and incubated with goat anti-mouse IgG Alexa-488 (Invitrogen; 1:500) and 
goat anti-human IgG Alexa-647 (1:500) for 1 h. Sections were then washed in PBS 3x for 10 min 
each and incubated with DAPI (Sigma) to label nuclei for 5 min at room temperature, washed 3x 
for 5 min each, and were mounted with Prolong Gold Antifade Reagent (Invitrogen). Slides were 
imaged using a Leica SP5 Confocal microscope.  
Note: This chapter is adapted from manuscript titled ‘Rational affinity maturation of anti-amyloid 
antibodies with high conformational and sequence specificity’. 
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 Isolation Of Anti-Tau And Anti-α-Synuclein Conformational Antibodies 
 
Introduction 
Protein misfolding and aggregation has been identified as a key event in several devastating 
diseases like Alzheimer’s and Parkinson’s disease (7-9,12). The aggregation of benign protein 
monomer into amyloidogenic oligomers, protofibrils and matured fibrils is linked to cellular death 
and disease progression in several pathologies termed as neurodegenerative diseases. Currently no 
cure exists for several of these neurodegenerative diseases. 
Antibodies are currently the most promising class of bio therapeutics with >100 antibodies 
approved for treating several types of disorders like cancer, auto-immune diseases, inflammatory 
diseases and viral infections (2). Conformational antibodies which selectively bind to toxic 
conformers of proteins are important for several different applications including diagnostic, 
therapeutic and better understanding of disease mechanisms (14). Although it is not trivial to 
generate conformational antibodies, many conformational antibodies have entered clinical trials 
for several neurodegenerative diseases. Traditional methods for making conformational antibodies 
include immunization, rational design and panning (31,36-38,44,94). Antibody isolation from 
human B-cell have also been used lately with great success (24-26). Even though many of these 
methods have worked in the past, they lack robustness. Their limited success is because of complex 
properties of amyloid aggregates like high hydrophobicity, poor diffusion, no control over antigen 
presentation and lack of molecular nature (1). 
We have sought to develop robust methods to develop conformational antibodies against 
tau and α-synuclein amyloid aggregates which are associated with several pathologies collectively 
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called tauopathies and synucleinopathies respectively. The aggregation of tau and α-synuclein 
proteins is a key event in these pathologies and fibrillar deposits are founds in brains of patients 
postmortem. We have developed high throughput screening methods using yeast surface display 
in combinations with powerful positive and negative selections to isolate antibodies with high 
affinity and conformational specificity (34,95). We have successfully generated antibodies whose 
conformational specificity are similar or better than many clinical antibodies against tau and α-
synuclein fibrils. We hope such methods would speed the discovery of conformational antibodies 
against several different protein targets. 
We have developed a novel nanoparticle-based flow cytometry-based selection technique. 
We first start with quantum dot (QD) functionalized with DIBO chemistry. Next, we selectively 
modify the glycan on a sequence specific antibody (also called capture antibody), introduce an 
azide group followed by covalently linking of capture antibody to QD by click chemistry. Next, 
we incubated the QD-antibody complex with our amyloid fibrils of interest to immobilize the 
fibrils on antibody (Fig. 3-1A). The QD-antibody-fibril complex is then incubated with yeast cells 
displaying antibody library followed by simple two color (antibody display and QD binding) 
FACS based selection (Fig. 3-1B).  
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Methods 
Antibody – quantum dot conjugation and sorting 
In addition to conventional positive selection against amyloid fibrils by magnetic activated 
cell sorting (MACS) discussed in Chapter 2, we developed a novel florescence activated cell 
sorting (FACS) based selection for amyloid aggregates. SiteClick Qdot 565 antibody labeling kit 
was purchased from Invitrogen (S10450). Capture antibodies Tau5 (expressed and purified in-
house) and MJFR1 (Abcam, ab138501) were conjugated to QD as per manufacturers’ guidelines. 
Tau fibrils SPR-329) and α-synuclein fibrils (SPR-317) were purchased from Stressmarq. 5 µg 
fibrils were first sonicated (5 mins; 30 s on, 30 s off) on ice and then incubated with 5 µL QD in a 
final volume of 200 µL at room temperature with end-over-end mixing for 2-3 hours. Post 
incubation, the fibril-QD complex was incubated with yeast cells displaying antibody library in 
1% milk with anti-myc antibody (1000x dilution) at room temperature with end-over-end mixing 
 
 
Figure 3-1: Illustration of novel QD based FACS selection for amyloid fibrils. 
(A) Quantum dots (red) are covalently attached to capture antibody (black) and incubated with amyloid fibril of interest to 
immobilize them. (B) FACS cytograms showing control/background and (right) binding population with fibril positive samples 
(right). 
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for 2-3 hours. Post primary incubation, the cells were washed once with ice-cold PBSB and 
incubated with goat anti-mouse AF488 on ice for 4 mins. Following secondary incubation, the 
cells were washed once with ice-cold PBSB and then sorted by flow cytometry. 
Antibody cloning and expression 
The antibody genes from the libraries were PCR amplified, cloned and sequenced in 
expression plasmids as discussed above in Chapter 2. Briefly, the scFv genes were PCR amplified 
from yeast mini-preps with forward primer containing NheI site and reverse primer containing 
HindIII site. Each PCR product was purified by DNA gel electrophoresis and digested with NheI-
HF and HindIII-HF. Next, it was purified by PCR clean-up, ligated into linearized Fc expression 
plasmid by T4 DNA ligase, transformed into competent DH5α cells, plated on LB agar plates 
supplemented with 100 µg/mL ampicillin and grown at 37 ᵒC overnight. The next day, individual 
colonies were picked, grown into LB media supplemented with ampicillin overnight at 37 ᵒC. 
Following day, the cultures were miniprepped followed by plasmid extraction and sequencing. 
The antibodies were expressed as Fc fusion proteins. The detailed procedure is discussed in 
Chapter 2. Briefly, HEK293-6E cells were transfected with antibody plasmids (15 µg) complexed 
with PEI (45 µg) and allowed to grow for 5-6 days. Next, the media was clarified by centrifuging 
the cells at 3000xg for 40 min and incubated with Protein A agarose beads overnight at 4 ᵒC with 
gentle mixing. Following days, the beads were collected in filter column under vacuum and 
washed with ~50 mL of PBS. Next, the protein was eluted from the beads by incubating with 0.1 
M glycine (pH 3.0) and buffer exchanged into 20 mM acetate (pH 5.0) by Zeba desalting columns. 
The proteins were filtered by 0.22 µm filters, aliquoted and stored at -80 ᵒC. Their purity was 
evaluated by SEC and concentration were measured by measuring absorbance at 280 nm. 
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Antibody binding analysis 
 Antibody binding analysis including affinity, conformational specificity and PSR binding 
were performed as discussed in Chapter 2. Briefly, for affinity analysis, the antibodies (at different 
concentrations) were incubated with dynabeads immobilized with amyloid aggregates. The 
binding was performed in 1% milk at room temperature for 3 h with mild agitation. Next, the beads 
were washed once with ice-cold PBSB and incubated with goat anti-human Fc AF647 on ice for 
4 mins. Following secondary incubation, the beads were washed once and analyzed by flow 
cytometry. For conformational specificity analysis, first the antibody (10 nM) was incubated with 
different concentration of soluble monomer at room temperature for 1 h. Next, beads immobilized 
with aggregates were added to this mixture and further incubated for 3 h at room temperature with 
mild agitation. Next, the beads were washed once, incubated with goat anti-human AF647, washed 
once again and analyzed by flow cytometry. For PSR binding, the antibodies were immobilized 
on Protein A beads overnight at 4 o C. The followed day, the beads were washed once and incubated 
with biotinylated PSR. For incubation, the beads were washed once, incubated with streptavidin 
AF647, washed once more, and analyzed by flow cytometry. 
Results 
Anti-α-synuclein antibodies 
The lead clone aS2.1 was discovered in single chain variable fragment (scFv) format from 
non-immune library. It retained the binding to α-synuclein aggregates when we re-formatted into 
IgG format with human IgG1 framework. Based on this exciting result, we decided to evaluate this 
antibody further in IgG format only. First, we looked at binding affinity against recombinant α-
synuclein fibrils and our antibody aS2.1 showed high binding (EC50 – 24 nM) which was 
comparable to clinical antibody Cinpanemab (EC50 of ~10 nM) (Fig. 3-2A). Following up on these 
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exciting results, we next evaluated conformational specificity analysis like described in Chapter 2 
and encouragingly, our antibody showed superior conformational specificity than Cinpanemab 
(Fig. 3-2B). We next evaluated our antibody for non-specific/off-target binding. We find our 
antibody aS2.1 as well as Cinpanemab shows medium levels of PSR binding (Fig. 3-2C). 
Although, we are unsure of the exact implications of this result, we suspect this might influence 




Figure 3-2: Binding analysis of α-synuclein antibodies. 
Bead based affinity (A), conformational specificity (B) analysis of anti-α-synuclein antibodies aS2.1 and clinical antibody 
Cinpanemab. (C) Off-target/PSR binding analysis of aS2.1, Cinpanemab compared to control clinical antibody Emibetuzumab 
and approved drug Elotuzumab. 
 
Anti-tau antibodies 
We also isolated conformational anti-tau antibody ATA1 using the similar methods 
described in Chapter 2 and above. The lead clone ATA1 displayed high conformational specificity 
but modest affinity. Next, we designed three CDR (L1, H1 and H2) focused soft randomization 
sub-libraries where at specific sites, we sampled the wild-type residue (~50%) and other amino 
acids (~50%). Next, we went through two rounds of selection against tau aggregates. In round 1, 
we performed MACS where immobilized tau aggregated on dynabeads as described in Chapter 2. 
In round 2, we performed FACS with QD-tau conjugates as described above. Following sort 2, we 
 68 
amplified individual CDR sequences from L1, H1 and H2 libraries, combined them using overlap 
extension PCR and made a new library where we combined the beneficial mutations from three 
CDR libraries. We next went through four rounds of screening with the new library. In round 1, 
we performed MACS with tau aggregates immobilized on dynabeads. In round 2, we performed 
FACS with QD-tau conjugates. In round 3, we performed a negative selection against tau monomer 
at 10 nM by collecting display with low monomer binding population. In round 4, we performed 
FACS with QD-tau conjugate but at lower QD-tau concentration (reduced by 60%). Next, we 
amplified the antibody genes from our library by PCR, cloned them into soluble antibody 
expression plasmids, expressed the antibody as Fc-fusion proteins and evaluated them. We found 
that several of our affinity matured antibodies show higher affinity (EC50 - 0.2-1 nM) than wild 
type antibody ATA1 (EC50 – 10 nM). Interestingly, our affinity matured antibodies also showed 
affinity similar or higher than clinical antibody Zagotanemab (EC50 – 0.5 nM) (Fig. 3-3A). We 
next evaluated our antibodies for conformational specificity in monomer competition assay as 
described in Chapter 2. We find that all our antibodies including the wild type and affinity matured 
variants retained the highest levels of conformational specificity similar to reagent antibody TNT1 
and clinical antibody Zagotanemab (Fig. 3-3B). These are two of the most conformational 
antibodies reported for tau amyloid aggregates. Next, we evaluated off-target binding for our 
clones by evaluating their binding to PSR. We observed that our antibodies show low levels of 





Figure 3-3: Binding analysis of tau antibodies. 
Bead based affinity (A), conformational specificity (B) analysis of anti-tau antibodies; ATA1,WT (wild type), affinity matured 
clones ATA1.458.3, 458.5, 459.3 and clinical antibody Zagotanemab and reagent antibody TNT1. (C) Off-target/PSR binding 
analysis of anti-tau antibodies compared to control clinical antibody Emibetuzumab and approved drug Elotuzumab. In (B) we 
report the median values from two independent repeats and the error bars are standard deviation. 
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Discussion and future work 
We were able to successfully isolate and engineer conformational antibodies against tau 
and α-synuclein protein aggregates. Such antibodies could be used for both therapeutic and 
diagnostic applications in additional to further our understanding diseases’ pathology. Although, 
conformational antibodies are not trivial to isolate, their importance to this field seems 
underappreciated. We have discovered novel strategies to isolate conformational antibodies which 
showed sets of properties similar or better than several clinical stage antibodies. Our tau antibodies 
how similar affinity (EC50 values of ~0.5-1 nM) and conformational specificity to clinical antibody 
Zagotanemab. Our α-synuclein antibodies show similar affinity (EC50 values of ~10-20 nM) but 
superior conformational specificity to clinical antibody Cinpanemab. We hope such systematic 
selection tools would speed the screening and selection of high affinity and conformational 
antibodies against amyloid aggregates.  
There are multiple aspects of our work which would be highly interesting to pursue. It 
would be very informative to evaluate the binding epitope of these antibodies since they bind to 
conformational epitope. It would be interesting to see if our antibodies recognize a novel epitope 
or ones already reported in literature. Next, it would be exciting to check if our antibodies can bind 
to pathological aggregates from transgenic mice. We do have some evidence for our tau and α-
synuclein antibodies recognizing pathological fibrils from transgenic mice in immunodot blot 
assay (data not shown), these experiments would need to be repeated to make sure the results are 
reproducible. Ultimately, evaluating these antibodies against pathological fibrils from human brain 
tissue in different assay formats like immunodot blots, western blots and immunofluorescence 
would be the final test.as it has been shown that pathological fibrils from transgenic mice and 
human brains have different structures. 
 71 
Antibody specificity is a poorly defined concept since it depends on the nature of non-
specificity molecule being using. We define non-specificity as binding to PSR which is a complex 
mixture of proteins, lipids, carbohydrates from CHO cell membranes (63,96). Our conformational 
anti-α-synuclein antibody aS2.1 seems to have modest PSR binding. A possible reason is the Fv 
(variable domain) net charge which has been to be a strong determinant of an antibody’s non-
specificity (64). Many of clinical stage antibodies and drugs with low levels of non-specificity 
have Fv charge of +1.5±2.5 (52,96) and the charge of aS2.1 is +4.1. In comparison, our tau 
antibodies have a range of Fv charge +1-5.1 but have low levels of PSR binding. This would 
suggest that in addition to charge which mainly contributes to electrostatics interactions, other 
modes of interactions like hydrophobic, hydrogen bonding, van der Waals’s might also be playing 
an important in governing specificity of these antibodies. Detailed animal experiments will have 
to be performed to determine the pharmacodynamics properties of these antibodies. 
Conformational anti-α-synuclein antibody aS2.1 has high affinity, but it would be very 
attractive to perform affinity maturation to further improve it. Surprisingly, this antibody was 
isolated during initial discovery using a human non-immune library from initial discovery 
campaign. It would serve as a high-quality lead for further affinity maturation. It is also worth 
considering methods for reducing the non-specific binding for this antibody during affinity 
maturation. This can be potentially performed in multiple different ways but the easiest and the 
most effective way would be to perform negative selection again PSR reagent and incorporate it 
during the affinity selections. The goal would be to further improve the affinity and off-target 
binding for this antibody while maintaining the conformational specificity which are the some of 
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 Directed Evolution Of Potent Neutralizing Nanobodies Against SARS-CoV-2 
Using CDR-Swapping Mutagenesis 
 
Introduction 
 The COVID-19 pandemic has resulted in widespread interest in developing antibodies and 
other affinity reagents that recognize the SARS-CoV-2 virus with high affinity and specificity for 
diagnostic and therapeutic applications. Most antibody generation efforts against SARS-CoV-2 
have involved either immunizing animals (Alsoussi et al., 2020; Hanke et al., 2020; Hansen et al., 
2020) with the spike (S1) protein [or receptor-binding domain (RBD) thereof] or isolating antigen-
specific antibodies from humans after infection and generation of neutralizing antibodies (Hansen 
et al., 2020; Shi et al., 2020; Wu et al., 2020). These approaches have yielded diverse types of 
antibodies for sensitive virus detection and potent inhibition of viral infection, including multiple 
antibodies now being used as therapeutics in humans (Baum et al., 2020a; Chen et al., 2020; 
Hansen et al., 2020). 
Despite the many strengths of in vivo antibody generation methods, they possess limitations 
relative to in vitro antibody generation methods, including those that use antibody display 
technologies such as phage and yeast surface display. The most important limitation is that in vivo 
methods lack the ability to robustly control antigen presentation to the immune system (Boder et 
al., 2000; Bradbury et al., 2011; Foote and Eisen, 2000; Tiller and Tessier, 2015). This, in turn, 
limits the ability to use such methods to select antibodies with pre-defined affinities, specificities 
and functional activities that are optimal for different applications. Even antibodies generated in 
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vivo are commonly affinity matured using in vitro display methods to achieve ultra-high affinities 
and/or cross species reactivities (Jackson et al., 1995).  
We have evaluated the potential of directed evolution methods for selecting high-affinity 
nanobodies against the SARS-CoV-2 spike protein from a nonimmune library (McMahon et al., 
2018). In particular, we tested if nanobody variants could be identified that would possess similar 
or superior affinities and neutralizing activities relative to a potent SARS-CoV-2 neutralizing 
nanobody (Ty1) generated via immunization [Ty1 (Hanke et al., 2020)] and a potent neutralizing 
SARS-CoV-2 human antibody isolated after infection [CB6 (Shi et al., 2020)]. Herein, we report 
an unexpected finding that high-affinity nanobodies can be isolated from nonimmune libraries by 
complementarity-determining region (CDR) swapping between low-affinity lead clones without 
additional mutagenesis. We demonstrate that this surprising finding, which was initially 
discovered by accident due to inadvertent recombination of two low-affinity lead clones, can be 
easily employed in a systematic manner during initial library sorting to identify high-affinity 
nanobodies without the need for subsequent affinity maturation.  
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Results 
In vitro discovery and affinity maturation of potent neutralizing nanobodies  
A synthetic nanobody library was first systematically sorted to isolate nanobodies that bind to 
the RBD of the SARS-CoV-2 spike protein S1 subunit (residues V16-R685; GenBank ID 
QHD43416; Fig. 4-1). This library has been previously reported for use in isolating nanobodies 
that bind to a diverse range of antigens (McMahon et al., 2018). For use in this study, the library 
was transferred to a yeast surface display system in which the nanobody N-terminus is linked to 
Aga2. We found that this Aga2 display system increased the percentage of yeast cells within the 
library that display nanobodies on the cell surface compared to a GPI anchor display system. The 
naïve library was first sorted against a soluble biotinylated SARS-CoV-2 RBD via magnetic-
activated cell sorting (MACS) to initially enrich the library and reduce the diversity to a level that 
could be feasibly processed by fluorescence-activated cell sorting (FACS). The enriched library 
was then sorted by FACS five times against RBD-Fc, biotinylated RBD or spike protein trimer. 
We found that the use of a bivalent antigen, RBD-Fc, was necessary for the first three rounds of 
FACS in order to distinguish a clear binding population within the library. Biotinylated RBD or 
spike protein trimer was used in later rounds of sorting after greater enrichment of a binding 




Figure 4-1: Summary of the discovery and affinity maturation of nanobodies against the spike protein of SARS-CoV-2. 
A synthetic nanobody library displayed on yeast was screened against the receptor-binding domain (RBD), spike (S1) protein 
and spike protein trimer of SARS-CoV-2 by MACS and FACS. Two lead clones (KA1 and KC3) were identified, and affinity 
matured using error-prone PCR. The sub-libraries were screened against the S1 protein by FACS to isolate nanobody variants 
(KA1.ep1, KC3.ep3 and KC3.ep5) with superior binding activity relative to a potent neutralizing nanobody generated via 
immunization (Ty1). 
 
Next, unique nanobody sequences that were enriched due to library sorting were identified via 
Sanger sequencing, expressed on the yeast surface, and tested for binding to biotinylated S1 protein 
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(50 nM). Two lead clones were selected from a sort against the RBD (KA1) and spike protein 
trimer (KC3) for further examination and affinity maturation. A third lead clone was also observed 
in sequencing from the spike protein trimer sort (KC1) which possessed more modest affinity 
compared to the two selected lead clones. The lead clones have the same frameworks because the 
library consists of nanobody variants with a common framework and diversity only in all three of 
the CDRs (McMahon et al., 2018). The two selected lead nanobodies have similar sequences for 
CDR1 with only one residue difference between them (Fig. 4-2). However, the sequences of CDR2 
differ by five residues, and the sequences of HCDR3 differ by eight residues as well as minor 
differences in length (13 residues for KA1 and 11 residues for KC3). 
 
 
Figure 4-2: Affinity-matured nanobodies possess a combination of CDRs from the two lead clones. 
(A) Affinity maturation of lead nanobodies KA1 and KC3 via error-prone PCR results in nanobody variants that possess one 
CDR from each lead nanobody [CDR2 (red) from KA1 and CDR3 (blue) from KC3] in addition to one CDR [CDR1 (green)] 
that only differs by a single mutation. (B) Nanobody sequences (Kabat numbering) for the three affinity-matured variants. 
Residues that are different than KA1.ep1 are indicated with an amino acid letter. 
 
KA1 and KC3 were then affinity matured using error-prone PCR at a low mutational frequency 
of approximately 1.2-1.5 mutations per nanobody on average (Fig. 4-1). Four rounds of FACS 
were performed to select for clones with improved affinity for the S1 protein. The concentration 
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of S1 antigen was decreased in each subsequent round until the library was enriched for superior 
binding relative to that of a leading SARS-CoV-2 nanobody (Ty1) with potent neutralization 
activity that was generated via immunization (Hanke et al., 2020). In the final round of sorting, the 
enriched nanobodies displayed clear binding at 100 pM S1, and the observed binding was stronger 
than Ty1. Only cells which bound at levels higher than that observed for Ty1 were collected. 
Clones were isolated from these terminal sorts for analysis and Sanger sequenced. Unexpectedly, 
all nine unique clones contained CDR2 from KA1 and CDR3 from KC3 (Fig. 4-2), including one 
clone (KA1.ep1) without any additional mutations in the CDRs or framework regions. KC3.ep3 
and KC3.ep5 both contained a few (2-3) additional mutations in their CDRs and frameworks 
resulting from error-prone PCR (Fig. 4-2). Herein, we refer to the replacement of one or more 
CDRs in a given nanobody (e.g., CDR2 in nanobody #1) with one or more CDRs from another 
nanobody (e.g., CDR2 from nanobody #2) as CDR swapping.  
CDR-swapped nanobodies display large increases in neutralization activity and affinity 
Both lead and affinity-matured clones were next analyzed for their ability to neutralize SARS-
CoV-2 infection as nanobody-Fc fusion proteins using a lentivirus-based SARS-CoV-2 
pseudovirus assay (Fig. 4-3A). The nanobody-Fc fusion proteins were produced in HEK 293-6E 
cells and isolated at high purity via Protein A chromatography. Their neutralization activity was 
directly compared to that of two previously published neutralizers, namely a nanobody [Ty1 
(Hanke et al., 2020)] and an antibody [CB6 (Shi et al., 2020)]. Strikingly, the three affinity-matured 
clones demonstrated dramatic (>300-fold) improvement in neutralization activity relative to their 
parental nanobodies (Fig. 4-3A). Moreover, the affinity-matured variants displayed complete 
neutralization at concentrations lower than for Ty1 and CB6. KA1.ep1 (IC50 of 4.8±2.6 ng/mL), 
KC3.ep3 (IC50 of 1.9±1.2 ng/mL), and KC3.ep5 (IC50 of 2.3±1.3 ng/mL) displayed the lowest IC50 
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values, with KC3.ep3 being the most potent neutralizer (Fig. 3-3A). The IC50 values determined 
for Ty1 (IC50 of 16±7 ng/mL) and CB6 (IC50 of 23±6 ng/mL) were comparable to those previously 




Figure 4-3: Affinity-matured nanobodies potently neutralize SARS-CoV-2 pseudovirus and live virus. 
(A) Neutralization results for nanobodies as bivalent Fc-fusion proteins (KA1, KC3, KA1.ep1, KC3.ep3, KC3.ep5 and Ty1) 
and antibodies (CB6) for inhibiting pseudovirus infectivity in a luciferase-based, HEK293T reporter cell line. Pseudovirus 
particles were pre-incubated with antibodies, added to reporter cells, and luciferase signal was measured after 48 h. (B) 
Neutralization results for nanobodies as bivalent Fc-fusion proteins (KC3.ep3, Ty1) and antibodies (CB6) for inhibiting live 
virus infection of VeroE6 cells. Nanobody and antibody dilutions were tested in eight replicate wells each. After cells were 
incubated with virus and nanobodies or antibody for 3 d, the cells were examined microscopically for visible cytopathic effect. 
Wells with any degree of visible, virus-induced cytopathic effect were scored as positive for infection. In (A), the data are 
averages of 4-5 repeats and the error bars are standard deviations. In (B), the data are averages of 2-4 repeats, and the error 
bars are standard deviations. 
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Based on the promising results from the pseudovirus assay, we further examined the 
neutralization activity of KC3.ep3 and Ty1 (as Fc-fusion proteins) and CB6 (IgG) against live 
SARS-CoV-2 virus (Fig. 4-3B). Neutralization of the live virus was determined by observing the 
cytopathic effect of the virus on VeroE6 cells. Measurement of neutralization activity using 
cytopathic effect has been previously observed to result in higher IC50 values than those reported 
using other detection methods for both live virus and pseudovirus (Shi et al., 2020). Nevertheless, 
our best affinity-matured variant (KC3.ep3) was significantly more potent at inhibiting the live 
virus (IC50 of 39±4 ng/mL) than Ty1 (IC50 of 211±42 ng/mL) and CB6 (IC50 of 655±287 ng/mL). 
These results are consistent with the pseudovirus assay and demonstrate the potent neutralization 




Figure 4-4: Potent neutralizing nanobodies display high monovalent and bivalent affinities for the SARS-CoV-2 receptor-
binding domain. 
(A) Monovalent binding of nanobodies displayed on the surface of yeast to biotinylated SARS-CoV-2 receptor-binding domain. 
(B) Bivalent binding of nanobodies (Fc-fusion proteins) and antibodies to biotinylated SARS-CoV-2 receptor-binding domain 
immobilized on magnetic beads. The results are averages from three independent experiments and the error bars are standard 
deviations. 
 
We also characterized the affinities for our matured nanobodies relative to their parental 
nanobodies in the monovalent and bivalent formats (Fig. 4-4). Monovalent affinities of the 
nanobodies for the SARS-CoV-2 RBD were examined using yeast surface display (Figs. 4-4A). 
The different monovalent nanobodies expressed on the yeast surface (as Aga2-nanobody fusions) 
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at similar levels. Notably, the monovalent affinities of the affinity-matured nanobodies (KDs of 
5.1-5.5 nM) were superior to leading nanobodies generated in vivo (KDs of 8-19 nM), and much 
higher than the parental nanobodies (KDs >100 nM). We also observed similar differences for the 
apparent affinities (EC50s) of bivalent nanobodies (Fig. 4-4B).  These latter experiments were 
performed using nanobodies formatted as soluble Fc-fusion proteins and RBD immobilized on 
magnetic Dynabeads. The affinity-matured nanobodies displayed stronger binding (EC50s of 34-
48 pM) than the previously reported nanobodies (EC50s of 55-69 pM for Ty1 and VHH-72) and 
antibodies (69-78 pM for CB6 and CR3022), and much stronger binding (>20-fold improved 
affinity) than the parental nanobodies (>1000 pM for KA1 and KC3). In summary, the affinity-
matured nanobodies demonstrate improved monovalent and bivalent affinities compared to 
leading nanobodies and antibodies generated in vivo, which is consistent with their superior 




Figure 4-5: Affinity-matured nanobody recognizes an epitope in the receptor-binding domain that overlaps with epitopes 
recognized by ACE2 and other potent SARS-CoV-2 neutralizing nanobodies and antibodies. 
Bivalent nanobodies (KC3.ep3, VHH-72 and Ty1), antibodies (S309, CR3022, CB6 and C119) and ACE2 were pre-incubated 
with biotinylated receptor-binding domain of SARS-CoV-2 (5 nM) over a range of nanobody, antibody and ACE2 
concentrations, and then the mixtures were added to yeast cells displaying monovalent KC3.ep3. The % bound receptor-binding 
domain is reported relative to the % bound in the absence of pre-blocking. The results are averages from three independent 
repeats and the error bars are standard deviations. 
 
KC3.ep3 recognizes an epitope in the receptor-binding domain common to other potent 
neutralizers 
 The RBDs from the SARS-CoV-2 and SARS-CoV viruses share >70% sequence similarity 
(Tian et al., 2020). It has been observed that some antibodies, including VHH-72, CR3022 and 
S309, bind to the RBDs of both viruses (Pinto et al., 2020; Tian et al., 2020; Wrapp et al., 2020). 
Therefore, we evaluated the affinity of monovalent KC3.ep3 to the RBDs of SARS-CoV and 
SARS-CoV-2 to compare its specificity relative to VHH-72. Both KC3.ep3 and VHH-72 
demonstrated strong binding to the SARS-CoV-2 RBD, but KC3.ep3 did not show detectable 
binding to the RBD of SARS-CoV, indicating that KC3.ep3 recognizes an epitope that is unique 
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in SARS-CoV-2 RBD, while VHH-72 strongly recognizes the SARS-CoV RBD (KD of 1.6±0.6 
nM), indicating that VHH-72 and KC3.ep3 recognize distinct RBD epitopes. 
 We further probed the epitope of KC3.ep3 by examining its competition for binding to the 
RBD of SARS-CoV-2 with the ACE2 receptor, previously reported nanobodies (Ty1 and VHH-
72), and antibodies which recognize distinct epitopes on the SARS-CoV-2 RBD [CB6 with class 
1 epitope (Shi et al., 2020), C119 with class 2 epitope (Barnes et al., 2020), S309 with class 3 
epitope (Pinto et al., 2020), and CR3022 with class 4 RBD epitope (Yuan et al., 2020); Fig. 3-5]. 
Soluble biotinylated RBD (5 nM) was preincubated with soluble ACE2 receptor or bivalent 
antibodies (nanobody-Fc fusions or IgGs) at a range of antibody concentrations (0.05-500 nM), 
and then these receptor-antigen or antibody-antigen complexes were incubated with yeast-surface 
displayed monovalent KC3.ep3.  
 Notably, the binding of monovalent KC3.ep3 to RBD was inhibited by preincubation of ACE2 
with RBD, suggesting that the KC3.ep3 and ACE2 binding sites on RBD overlap and explain the 
ability of KC3.ep3 to potently neutralize the virus (Fig. 3-5). Moreover, the binding of monovalent 
KC3.ep3 to RBD was strongly inhibited by preincubation of RBD with bivalent KC3.ep3, as 
expected. KC3.ep3 binding to RBD was also inhibited by bivalent Ty1, CB6 or C119, although 
not as strongly as for bivalent KC3.ep3. Thus, the epitope of KC3.ep3 appears to overlap with that 
of Ty1, CB6 (class 1 epitope) and C119 (class 2 epitope).  
  Conversely, monovalent KC3.ep3 binding was weakly impacted or even enhanced when the 
RBD was preincubated with bivalent VHH-72, S309 (class 3 epitope) and CR3022 (class 4 
epitope; Fig. 4-5), revealing that the epitope of KC3.ep3 does not overlap with these antibodies. 
The fact that KC3.ep3 and VHH-72 do not compete for binding is in agreement with our finding 
that KC3.ep3 recognizes an epitope in SARS-CoV-2 RBD that is absent in SARS-CoV RBD while 
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VHH-72 recognizes an epitope that is present in both RBDs. Likewise, CR3022 has been 
previously demonstrated to cross-react with both viruses (Tian et al., 2020), and most residues in 
its class 4 epitope are conserved between both viruses (Yuan et al., 2020), indicating that its epitope 
would also be expected to be distinct from that of KC3.ep3. Likewise, S309 has been observed to 
cross-react with SARS-CoV, and the absence of competition between KC3.ep3 and S309 also 
agrees with our observation that KC3.ep3 competes with ACE2 and previous observations that 
S309 does not compete with ACE2 (Pinto et al., 2020). 
Neutralizing nanobodies display drug-like biophysical properties  
For use in therapeutic and diagnostic applications, nanobodies need to be easily produced and 
possess favorable biophysical and biomanufacturing properties, including high stability, high 
solubility, low levels of aggregation, low non-specific binding and high expression levels. 
Therefore, we first quantified the expression yields of nanobodies in this study via transient 
transfection of HEK293 cells. It has been previously shown that this expression system can be 
used to express nanobody Fc-fusion proteins at yields ranging from ~20-140 mg/L (Zhang et al., 
2009). We observed similar high purification yields for the affinity-matured nanobodies obtained 
via directed evolution (~27-110 mg/L), which were also comparable to the purification yields for 
the nanobodies obtained via immunization (Ty1 and VHH-72; 52-85 mg/L). The purity (SDS-
PAGE) and homogeneity (size-exclusion chromatography) of the affinity-matured nanobodies 





Figure 4-6: Affinity-matured nanobodies display high stability and specificity. 
(A) Melting temperatures of bivalent nanobodies and antibodies evaluated via differential scanning fluorimetry. (B) Non-
specific binding of bivalent nanobodies and antibodies (immobilized on magnetic beads) was evaluated via incubation with 
biotinylated soluble membrane proteins from CHO cells and detection of non-specific binding via flow cytometry. Control 
antibodies with high (emibetuzumab) and low (elotuzumab) non-specific binding were also evaluated for comparison. The two 
control antibodies are not identical to the actual drugs, as they have the variable regions of the actual drugs and a common IgG1 
framework.  In (A) and (B), the results are averages from three independent repeats and the error bars are standard deviations. 
 
The stability of the affinity-matured nanobodies was also examined (Fig. 3-6A). It is a concern 
that mutations accumulated by nanobodies, and antibodies in general, during affinity maturation 
have an increased risk for reducing stability (Julian et al., 2017; Rabia et al., 2018; Shehata et al., 
2019). This is even more concerning for CDR-swapped variants with CDRs of different lengths, 
as observed for the CDR3-swapped variant KA1.ep1, because these changes could impact the local 
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structure of the nanobody. Therefore, we analyzed the folding stability (melting temperature, Tm) 
of the lead nanobody clones and their affinity-matured variants relative to previously reported 
SARS-CoV-2 nanobodies and mAbs. The lead nanobodies displayed high stabilities, as both KA1 
and KC3 displayed melting temperatures >68 °C (KA1 Tm of 71.3±0.4 °C and KC3 Tm of 68.3±1.0 
°C). Notably, the affinity-matured variants displayed similar stabilities (KA1.ep1 Tm of 69.5±0.8 
°C, KC3.ep3 Tm of 69.6±0.8 °C and KC3.ep5 Tm of 68.6±0.6 °C), suggesting that the affinity-
enhancing CDR swaps maintained high stability. Moreover, the stabilities of the affinity-matured 
nanobodies were similar to those for nanobodies generated via immunization (Ty1 Tm of 69.3±1.0 
°C and VHH-72 Tm of 69.1±0.6 °C). As expected, the stability of the mAbs (CB6 and CR3022) 
were higher (Tm values >77 °C) because of their stabilizing constant regions (CH1 and CL).  
Finally, the specificity (non-specific binding) of the affinity-matured variants was examined 
by testing their ability to bind complex mixtures of soluble membrane proteins obtained from 
HEK293 cells (Fig. 4-6B) (Xu et al., 2013). It has been previously reported that approved antibody 
drugs typically display lower levels of non-specific binding, including to soluble membrane 
proteins, than antibodies that either failed in clinical development or are still in development (Jain 
et al., 2017). Further, low antibody specificity has also been shown to correlate with poor 
pharmacokinetic properties (Hötzel et al., 2012). Notably, the lead nanobodies and affinity-
matured variants in this work displayed extremely low binding to soluble membrane proteins. The 
levels of binding observed were comparable to other SARS-CoV-2 nanobodies and antibodies 
generated in vivo and similar to a clinical-stage mAb with low levels of non-specific binding 
(elotuzumab), and much lower than a clinical-stage antibody with high levels of non-specific 
binding (emibetuzumab). These results collectively demonstrate that the potent neutralizing 
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nanobodies reported in this work have drug-like biophysical properties that are similar to SARS-
CoV-2 nanobodies and antibodies generated by the natural immune system.  
Systematic CDR-swapping mutagenesis for identifying high-affinity nanobodies without 
affinity maturation 
Given that unintentional CDR swapping between low-affinity lead nanobodies led to 
unexpectedly large increases in affinity, we next asked whether the introduction of intentional 
CDR swapping during the initial library sorting process would enable identification of high-
affinity nanobodies without the need for lead clone evaluation and affinity maturation. Therefore, 
we isolated the enriched library of nanobody plasmids prior to the terminal sort of our original 
sorting efforts (after five rounds of sorting against RBD and related reagents; Fig. 4-1), shuffled 
their three CDRs via standard PCR methods (see Methods for details), and sorted the CDR-




Figure 4-7: Nanobodies with nanomolar monovalent affinities can be generated via CDR-swapping mutagenesis without the 
need for lead clone identification and subsequent affinity maturation. 
Nanobodies were selected from a nonimmune library with (KA1.ep1, K7.13, K7.19) or without (KC3, KA1, KC1) CDR-
swapping mutagenesis, and the selected clones were evaluated in terms of their monovalent binding affinities for the SARS-
CoV-2 receptor-binding domain. The results are averages from two independent experiments and the error bars are standard 
deviations. 
 
Encouragingly, Sanger sequencing revealed that this simple mutagenesis method is able to 
identify multiple known or promising high-affinity nanobodies. These include a high-affinity 
nanobody that we discovered in our initial two-step library sorting and affinity maturation process 
(KA1.ep1) as well as nanobodies not observed previously (K7.13 and K7.19). The most common 
nanobody identified was KA1.ep1, which is logical because this high-affinity nanobody is a CDR-
swapped version of KA1 and KC3 without any additional mutations. We also identified a 
nanobody (K7.19) that was a variant of KA1.ep1 with one mutation. Notably, we also identified a 
nanobody (K7.13) with a unique CDR3, which is particularly interesting because we originally 
identified a low-affinity lead clone (KC1) with the same CDR3 but with different CDR1 and CDR2 
loops. Our initial observations of CDR swapping in KA1.ep1, KC3.ep3 and KC3.ep5 resulted from 
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a combination of CDRs from KA1 and KC3. Similarly, K7.13 contains CDR1 and CDR2 from 
KA1 and CDR3 from KC1.  
Finally, we evaluated the monovalent affinities of the nanobodies generated by CDR-swapping 
mutagenesis (Fig. 4-7). Notably, the nanobodies identified from intentional CDR-swapping 
mutagenesis displayed single digit monovalent binding affinities (KD of 3-4 nM) that were similar 
to KA1.ep1. These binding affinities were much stronger than the lead clones identified in our 
original sorting efforts (KA1, KC1 and KC3) despite that the CDRs of the high-affinity clones are 
identical to or closely related to the low-affinity lead clones. In summary, these results indicate 
that CDR swapping between common framework nanobodies has great potential to enable the 
facile isolation of high-affinity nanobodies, and this mutagenesis strategy can be easily 
incorporated during the initial sorting process to avoid the need for lead clone evaluation and 
subsequent affinity maturation.  
Discussion 
 We have demonstrated that common framework, nonimmune nanobody libraries can be used 
in a surprisingly simple manner to generate high-affinity nanobodies without the need for lead 
clone identification or additional mutagenesis in the framework or CDRs. Some previous reports 
of antibodies against unrelated targets have optimized individual CDRs separately, and then 
combined the optimized CDRs to further increase affinity (Steidl et al., 2008; Yang et al., 1995). 
However, these studies are for antibodies that already have relatively high affinity and, thus, 
address a simpler challenge of affinity maturation and result in much lower synergistic 
improvements in affinity after CDR swapping than we observed in our studies. In contrast, our 
work addresses a more challenging problem of how to identify high-affinity clones without the 
need to first identify lead clones with modest affinity and select individual clones for affinity 
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maturation. We expect that this approach of combining multiple low affinity clones via CDR 
and/or framework swapping holds great potential for rapidly generating nanobodies and, more 
generally, antibodies with high affinity with much less effort than is typically required. Despite 
that this discovery was unintentional, we demonstrate that it is simple to perform CDR swapping 
using standard PCR methods, and it could be used as a facile method for identifying high-affinity 
clones, even without additional mutagenesis.  
 Compared to CDR swapping, we observed much smaller improvements in affinity from 
additional CDR and framework mutations (KC3.ep3 and KC3.ep5) due to error-prone PCR. 
Nevertheless, the average number of mutations incorporated by this error-prone PCR (1.2-1.5 
mutations per nanobody) was low in comparison to the changes incorporated though CDR 
swapping. A higher error rate could have the potential to introduce a greater number of beneficial 
mutations in combination with or following CDR swapping.   
The epitopes of our neutralizing nanobodies relative to previously reported neutralizing 
nanobodies and antibodies also deserve further consideration. The epitope is of particular interest 
in order to identify pairs of nanobodies or antibodies which bind to different sites and can therefore 
aid in the prevention of infection by SARS-CoV-2 escape mutants (Baum et al., 2020b; Greaney 
et al., 2020; Weisblum et al., 2020). Like KC3.ep3, the epitopes of several other potent neutralizing 
antibodies in the RBD have also been reported to overlap with the ACE2 binding site (Barnes et 
al., 2020). It is notable that KC3.ep3 competes with a class 1 antibody (CB6), indicating that CB6 
binds the RBD only in the “up” conformation and competes with ACE2. CB6 has been shown to 
sterically hinder ACE2 binding to RBD, and the epitope recognized by CB6 overlaps with the 
region bound by ACE2 (Shi et al., 2020). Further, class 1 antibodies have been observed to have 
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short (<15 residue) HCDR3 loops (Barnes et al., 2020). KC3.ep3 similarly has a CDR3 which 
consists of only 11 residues.  
The fact that KC3.ep3 also competes with a class 2 antibody (C119) indicates that C119 binds 
to the RBD in both the “up” and “down” conformations and also competes with ACE2. Consistent 
with its competition with class 1 and class 2 antibodies, the binding of KC3.ep3 was also reduced 
when the RBD was preincubated with ACE2 (Fig. 4-5). Thus, KC3.ep3 appears to recognize an 
epitope that overlaps with the ACE2 binding site and is common to potent neutralizing antibodies 
that also block ACE2 binding. KC3.ep3 competes similarly with a potent neutralizing nanobody, 
Ty1. Like class 2 antibodies, Ty1 has previously been demonstrated to reduce the ability of RBD 
to bind ACE2, and structural analysis indicates that Ty1 sterically hinders this binding when the 
RBD is in both the "up" and "down" conformations (Hanke et al., 2020). Moreover, preincubation 
of RBD with ACE2 did not reduce the ability of KC3.ep3 to bind RBD as strongly as preincubation 
with the class 1 and class 2 antibodies, indicating that the KC3.ep3 epitope does not completely 
overlap with the ACE2 binding site. 
However, KC3.ep3 does not compete for binding with antibodies that cross-react with both 
SARS-CoV and SARS-CoV-2, namely VHH-72, CR3022 and S309. CR3022 has been reported 
to be a class 4 antibody, indicating that it binds the RBD in the “up” conformation but does not 
compete with ACE2 (Barnes et al., 2020). Structural analysis has further shown that CR3022 binds 
to the SARS-CoV-2 RBD but does not compete for binding with ACE2, and CR3022 weakly 
neutralizes the SARS-CoV-2 virus (Yuan et al., 2020). Interestingly, the epitopes for CR3022 and 
VHH-72 overlap, but due to different angles of binding, VHH-72 indirectly hinders RBD binding 
to ACE2 while CR3022 does not (Wrapp et al., 2020). As both VHH-72 and CR3022 cross-react 
with the SARS-CoV RBD while KC3.ep3 does not, it would be expected that KC3.ep3 does not 
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recognize an overlapping epitope. Therefore, the reported epitopes are consistent with the lack of 
competition observed between KC3.ep3 and both CR3022 and VHH-72.  
The fact that KC3.ep3 also does not compete with a class 3 antibody (S309) also deserves 
further consideration. Class 3 antibodies can bind to the RBD in both the “up” and “down” 
conformations but do not compete with ACE2. Interestingly, the binding of KC3.ep3 was 
enhanced when RBD was incubated with S309 (Fig. 4-5). Given that KC3.ep3 competes with 
ACE2, its epitope would be expected to be distinct from that of a class 3 antibody, such as S309. 
Enhancement of neutralization activity has previously been reported for antibody cocktails 
composed of S309 and an antibody targeting as distinct epitope (Pinto et al., 2020). A pair of class 
1 and class 3 antibodies (Barnes et al., 2020), REGEN10933 and REGN10967, have previously 
been examined for combination as a cocktail (Baum et al., 2020b, 2020a). This analysis of the 
epitope of KC3.ep3 indicates that it is likely to compete with binding the SARS-CoV-2 RBD with 
class 1 and class 2 antibodies, but the observed enhancement of KC3.ep3 binding in the presence 
of S309 suggests that the combination of KC3.ep3 with a class three antibody could be beneficial 
in terms of affinity and potentially neutralization activity as well. 
 The identification of neutralizing nanobodies and antibodies which target SARS-CoV-2 
represents a rapidly evolving area of research. As such, consideration should also be given to the 
affinity and neutralization activities of the nanobodies that we report in context of previously 
reported nanobodies and antibodies in addition to the targeted epitope. In terms of nanobody 
affinity and neutralization activity, a broad range of these properties has been reported in the 
literature. Several recent studies have reported nanobodies that bind to the SARS-CoV-2 virus 
(Chi et al.; Hanke et al., 2020; Huo et al., 2020; Schoof et al., 2020; Wrapp et al., 2020; Xiang et 
al., 2020). Multiple studies have reported nanobodies isolated from naïve and synthetic libraries 
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using various in vitro panning and sorting strategies (Chi et al.; Custódio et al., 2020; Huo et al., 
2020; Schoof et al., 2020). Similar to the strategy that we have reported here, some of these studies 
have incorporated affinity maturation in order to further improve the properties of the isolated lead 
candidates (Huo et al., 2020; Schoof et al., 2020). Direct comparison between various studies and 
comparison with the results reported here are complicated by the use of different experimental 
methodologies and nanobody constructs (e.g., monovalent vs bivalent). Nevertheless, the 
nanobodies that we report appear to compare favorably in terms of affinity and neutralization 
activity to those reported previously. Similar to several nanobodies previously isolated using in 
vitro methods (Chi et al.; Custódio et al., 2020; Huo et al., 2020), the nanobodies we report here 
demonstrate nanomolar monovalent affinities (Fig. 4-4A). Direct comparison to nanobodies and 
antibodies isolated in three previous studies also indicates that the nanobodies reported here have 
comparable or improved affinities (Fig. 4-4) and neutralization activities (Fig. 4-3) to multiple 
leading nanobodies isolated from immunization [VHH-72 (Wrapp et al., 2020) and Ty1 (Hanke et 
al., 2020)] and an antibody isolated from infected humans [CB6 (Shi et al., 2020)]. While recent 
studies also demonstrate that extensive, large-scale efforts can identify nanobodies with higher 
affinities and increased neutralization activities (Xiang et al., 2020), it would be simple to further 
affinity mature our nanobodies to achieve even higher affinities. More generally, our findings 
demonstrate the power of directed evolution methods to rapidly generate high-affinity nanobodies 
with epitopes that overlap with leading neutralizing nanobodies and antibodies, and which result 
in highly potent neutralization activities.  
 Using the simple method of CDR swapping, we were able to improve the affinity of our lead 
clones (KD - 1-5 nM). This would further the make the process of affinity maturation more efficient 





Lead nanobody isolation and maturation 
 The original nanobody library (McMahon et al., 2018) was cloned into an Aga2-based yeast 
surface display plasmid (Julian et al., 2019). The nanobodies were expressed on the yeast surface 
as C-terminal fusion proteins to Aga2 (Aga2-nanobody). In the first round, MACS was performed 
against biotinylated RBD (bRBD) of SARS-CoV-2 (Acro, SPD-C82E9). 109 cells were incubated 
with 300 nM biotinylated RBD in PBS supplemented with 1 g/L BSA (PBSB) and 1% milk at 
room temperature for 3 h. Post incubation, the cells were washed once and incubated with 
streptavidin microbeads (Miltenyi, 130-048-141) with gentle rocking for 30 mins at 4 ᵒC. 
Following incubation, the cells were washed once with ice-cold PBSB and passed through a 
MACS column under magnetic field to isolate cells bound to beads. The captured beads were 
washed once with ice-cold PBSB while employing the magnetic field. After washing, the beads 
were eluted into low pH SDCAA (20 g/L of dextrose, 6.7 g/L of yeast nitrogen base without amino 
acids, 5 g/L of casamino acids, 16.75 g/L of sodium citrate and 4 g/L of citric acid) liquid media 
and grown at 30 ᵒC for 2 d. All subsequent sorting was performed by FACS. In rounds 2, 3 and 4, 
a selection was performed against RBD-Fc (Acro, SPD-C5255; 100 nM for rounds 2 and 3 and 50 
nM for round 4 respectively). In round 5, a selection against bRBD was performed at 100 nM 
followed by selection against 100 nM bRBD, 100 nM bS1 (S1 domain of SARS-CoV-2; Acro, 
S1N-C82E8) or 50 nM S protein trimer (Acro, SPN-C52H8).  
 Three lead nanobodies (KA1, KC3 and KC1) from the initial discovery campaign were isolated 
with modest affinities. Two of these clones (KA1 and KC3) were affinity matured by first 
preparing error-prone PCR libraries as previously described (Chao et al., 2006). Briefly, the DNA 
region encoding only KA1 or KC3 was amplified using Taq DNA Polymerase with Standard Taq 
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Buffer (New England Biolabs, M0273L) in the presence of non-natural nucleotides, 8-Oxo-2'-
deoxyguanosine-5'-Triphosphate (TriLink Biotechnologies, N-2034-1) and 2’-Deoxy-P-
nucleoside-5'-Triphosphate (TriLink Biotechnologies, N-2037). Ten PCR cycles were used to 
amplify the DNA, and nanobody DNA was gel purified in a 1% agarose gel. To increase the 
number of mutations, DNA was amplified using Q5 High-Fidelity DNA Polymerase (New 
England Biolabs, M0491L), gel purified, and a second error-prone PCR with Taq DNA 
polymerase (New England Biolabs, M0320L) was performed under identical conditions. DNA 
encoding the region of plasmid surrounding KA1 or KC3 was added by overlap PCR. Total insert 
DNA was then amplified, and DNA was transformed into EBY100 as previously described 
(Benatuil et al., 2010). Four rounds of FACS selections were performed for each library, and the 
antigen concentration was progressively reduced, including 50 nM biotinylated S1 in round 1, 10 
nM biotinylated S1 in round 2, 2 nM biotinylated S1 in round 3, and 100 pM biotinylated S1 in 
round 4. 
CDR-swapping mutagenesis and clone evaluation 
 We also intentionally introduced CDR-swapping mutagenesis after sort 5 of the initial 
discovery campaign. DNA was isolated from yeast cells that were collected after the fifth sort of 
the initial synthetic library. DNA segments of the nanobody gene comprising CDR1 (framework 
1 to framework 2), CDR2 (framework 2 to framework 3) and CDR3 (framework 3 to framework 
4) were PCR amplified to facilitate overlap PCR. The DNA encoding each CDR was then mixed 
at an equal mass ratio, and overlap PCR was used to reassemble and amplify DNA encoding the 
entire nanobody. The CDR-swapped nanobody DNA library was inserted into the yeast display 
plasmid by homologous recombination. The transformation efficiency for this CDR-swapped 
nanobody library was ~5 x 107. Next, two rounds of sorting were performed by FACS using 
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biotinylated RBD (100 nM in sort 1 and 10 nM in sort 2). Yeast cells collected from the terminal 
sort were miniprepped and Sanger sequenced.  
Nanobody-Fc expression and purification 
 Yeast cells from the terminal rounds of sorting were mini-prepped (Zymo Research, D2004) 
and plasmids were recovered. Nanobody genes were amplified by performing PCR on yeast mini-
prepped DNA with forward and reverse primers containing NheI and HindIII restriction sites, 
respectively. The PCR products were purified via a 1% agarose gel and extracted with DNA 
purification kit (Qiagen, 28704). The nanobody genes were then digested with NheI-HF (New 
England Biolabs, R3131L) and HindIII-HF (New England Biolabs, R3104L), as instructed by the 
manufacturer’s protocol, followed by purification (Qiagen, 28104). Nanobody-Fc expression 
plasmid was digested with NheI-HF and HindIII-HF, as instructed by the manufacturer’s protocol, 
followed by treatment with calf intestinal alkaline phosphatase (New England Biolabs, M0525L). 
The digested vector was purified by 1% agarose gel electrophoresis and followed by DNA 
extraction. The digested vector and inserts were ligated with T4 ligase (New England Biolabs, 
M0202L) followed by transformation into competent DH5α cells. Transformed cells were plated 
on LB plates supplemented with ampicillin (100 ug/mL) overnight at 37 ᵒC. Individual colonies 
were picked and grown in LB media (with ampicillin) overnight followed by mini-prepping 
(Qiagen, 27106). Plasmids from colonies were sequenced using Sanger sequencing. 
 HEK 293-6E cells (National Research Council of Canada) were grown, maintained and 
passaged at a density of 1.5-2 million cells per mL in F17 media (Thermo Fisher Scientific, 
A1383502) supplemented with Glutamine (Invitrogen, 25030081), Kolliphor (Thermo Fisher 
Scientific, NC0917244) and G418 (Thermo Fisher Scientific, 10131035). Nanobody-Fc plasmid 
(15 g) was mixed with PEI (45 g) at room temperature with F17 media (without supplements) 
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for 10-15 min and added to cells at a density of 1.5-1.8 million cells per mL. Cells were fed with 
20% w/v yeastolate (BD Sciences, 292804) 24-48 h post transfection and were grown for an 
additional 2-4 d at 37 ᵒC. Post expression, media was harvested by centrifuging cells at 4000 xg 
for 40 min. Media was collected, transferred to new tubes and 0.5-1 mL Protein A bead (Thermo 
Fisher Scientific, 20333) slurry was added followed by gently rocking at 4 ᵒC overnight. Protein 
A beads were collected from media with filter columns (Thermo Fisher Scientific, 89898) under 
vacuum followed by washing with 50-100 mL of PBS. Protein was eluted from Protein A beads 
using 0.1 M glycine buffer (pH 3.0) followed by 1x buffer exchange into 20 mM acetate (pH 5.0) 
using Zeba desalting columns (Thermo Fisher Scientific, 89894). Proteins were then filtered using 
0.2 µm filters, aliquoted and stored at -80 ᵒC. Nanobody concentrations were evaluated by 
measuring absorbance at 280 nm and purity was evaluated by SDS-PAGE (Thermo Fisher 
Scientific, WG1203BOX). 
Pseudovirus neutralization analysis 
SARS-CoV-2 pseudovirus neutralization assay was adapted from a previous report (Crawford 
et al., 2020). To prepare SARS-CoV-2 pseudovirus particles, Lenti-X 293T cells (Takara, 632180) 
were seeded at 5x105 per well in 6-well plates in RPMI media supplemented with 10% Fetal 
Bovine Serum (FBS), 1% penicillin/streptomycin (P/S) and cultured at 37 °C with 5% CO2. Upon 
reaching a target confluency of 50-70%, cells were transfected with third generation lentivirus 5 
plasmid system (0.22, 0.22, 0.22, 1, or 0.34 µg respectively): HDM-Hgpm2 plasmid (BEI catalog 
number NR-52517) encoding HIV Gag-Pol under CMV promoter, HDM-tat1b plasmid (BEI 
catalog number NR-52518) encoding HIV Tat under CMV promoter, pRC-CMV-Rev1b plasmid 
(BEI catalog number NR-52519) encoding HIV Rev, pHAGE-CMV-Luc2-IRES-ZsGreen-W 
(BEI catalog number NR-52516) lentiviral transfer plasmid encoding co-expression of luciferase 
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and ZsGreen, pCMV3 SARS-CoV2 S Untagged Delta 19AA C-term plasmid encoding the SARS-
CoV-2 spike (S) protein with a 19-amino acid deletion at the C-terminus. 
At 24 h post-transfection, cell media was changed to fresh RPMI with 10% FBS and 1% P/S. 
At 72 h post-transfection, cell supernatant was collected and passed through a 0.45 µm filter to 
remove cellular debris. SARS-CoV-2 pseudovirus was then concentrated via Lenti-X Concentrator 
(Takara, 631232) without ultracentrifugation. Briefly, Lenti-X Concentrator was added to cell 
culture supernatant at a volume ratio of 1:3 and incubated overnight at 4 °C. The mixture was then 
centrifuged at 1500 xg for 45 min. Supernatant was discarded, and the pseudovirus pellet was 
resuspended in Opti-MEM media in a volume of 50 µL Opti-MEM per well of virus harvest.  
To determine virus titer, 293T-ACE2 cells (BEI resources catalog NR-52511) were seeded at 8,000 
cells per well in a 96-well plate in DMEM with 10% FBS and 1% P/S and cultured at 37 °C with 5% CO2. 
At 24 h post-seeding, cells were infected with varying dilutions of virus, diluted in DMEM media in the 
presence of 5 µg/mL polybrene, 10% FBS, and 1% P/S. At 48 h post-infection, the percentage of ZsGreen-
expressing cells was determined via flow cytometry using a Bio-Rad ZE5 cell analyzer and further 
corroborated via fluorescence microscopy. Tissue culture infectious units (TCIU) per mL of virus was then 
calculated.  
For neutralization assays, 293T-ACE2 cells were seeded at 8,000 cells per well in white bottom 
96-well plates (Corning, 3917) in DMEM (10% FBS and 1% P/S) and cultured at 37 °C with 5% 
CO2. At 24 h post-seeding, 293T-ACE2 cells were infected with 350 TCIU SARS-CoV-2 
pseudovirus per well in the presence of antibody treatments. Briefly, 4-fold serial dilutions of 
antibody were prepared, mixed with SARS-CoV-2 pseudovirus, and incubated for 1 h at 37 °C. 
Following this incubation, 293T-ACE2 cells were treated with SARS-CoV-2 pseudovirus-
antibody mixtures in the presence of 5 µg/mL polybrene. At 48 h post-infection, neutralization 
activity was determined via bioluminescence detection using a microplate reader. Briefly, 96-well 
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plates were equilibrated to room temperature for 15 min. Media volume in each well was then 
reduced to 80 µL via micropipette. Luciferase substrate (80 µL; Promega ONE-Glo, E6110) was 
added to each well, the plate was incubated at room temperature for 10 min, and bioluminescence 
was detected using Molecular Devices SpectraMax microplate reader with 500 millisecond 
integration/well. 
Live virus neutralization analysis 
For antibody neutralization assays, 96-well plates were seeded with VeroE6 (ATCC CRL1586) 
cells at 10,000 cells per well and incubated at 37 ˚C and 5% CO2 for 24 h. Antibodies were diluted 
in DMEM with 2% FBS in 96-well plates at a 2x final concentration in a volume of 50 µL. Cell 
culture plates and antibody dilution plates were then transferred to a BSL3 facility. 50 µL of diluted 
SARS-CoV-2 (2000 pfu/mL or 100 pfu/well) was added to each well containing 50 µL of diluted 
antibodies. The antibody-virus mixtures were incubated at 37˚C for 1 h. Growth media was then 
aspirated from cell culture plates and replaced with 100 µL of the virus-antibody solution. 
Antibody dilutions were tested in eight replicate wells each. Plates were incubated at 37 ˚C and 
5% CO2 for 3 days, then examined microscopically for visible cytopathic effect (CPE). Wells with 
any degree of visible, virus-induced CPE were scored as positive. All antibody neutralization 
screening experiments were conducted following standard operating procedures of an approved 
Biosafety Level 3 Facility. 
Nanobody affinity and specificity analysis 
 The monovalent affinities for the nanobodies were evaluated in yeast surface display format. 
The nanobodies were expressed on the yeast surface as C-terminus fusion proteins (Aga2-
nanobody). For affinity measurements, 105 yeast cells per sample that express each nanobody were 
washed twice with PBSB and incubated with mouse anti-Myc antibody (1000x dilution) and 
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biotinylated RBD over a range of concentration in 1% milk at room temperature for 3 h. Post 
incubation, the cells were centrifuged at 2500 xg for 5 min followed by washing once with ice-
cold PBSB. Next, the cells were then incubated with goat anti-mouse IgG AF488 (200x dilution; 
Invitrogen, A11001) and streptavidin AF647 (1000x dilution; Invitrogen, S32357) on ice for 4 
min. Post-secondary antibodies incubation, cells were centrifuged and washed once with ice-cold 
PBSB, re-suspended in PBSB and evaluated on Bio-Rad ZE5 analyzer.  
For specificity analysis, the binding was evaluated for antibodies KC3.ep3 and VHH-72 to 
receptor-binding domain (RBD) of SARS-CoV (Acro, SPD-S52H6) and SARS-CoV-2 virus. The 
antigen binding was performed in similar way as described above. Post antigen binding, the cells 
were washed once with ice-cold PBSB and incubated with mouse anti-Myc (1000x dilution) and 
chicken anti-His (1000x dilution; Invitrogen, PA1-9531) antibodies on ice for 20 min. Post primary 
incubation, the cells were washed with ice-cold PBSB and incubated with goat anti-mouse IgG 
AF488 (200x dilution) and donkey anti-chicken IgY F(ab’)2 fragment AF647 (500x dilution; 
Jackson ImmunoResearch, 703-606-155) antibodies on ice for 4 min. Post-secondary incubation, 
the cells were washed once with ice-cold PBSB and evaluated by flow cytometry.  
For affinity measurements of soluble antibodies in the bivalent format, biotinylated RBD was 
first immobilized on streptavidin Dynabeads (Invitrogen, 11047). Antigen loading was 0.1 g 
protein for 107 beads in a final volume of 400 L. Beads were washed twice with PBSB and 
blocked with 10% milk in PBSB by end-over-end mixing at room temperature for 1 h. Post 
blocking, the beads were washed once with PBSB and incubated with varying concentrations of 
antibodies (105 beads per sample) in PBSB with 1% milk at room temperature for 3 h. After 
antibody incubation, the beads were centrifuged and washed once with ice-cold PBSB followed 
by incubation with goat anti-human IgG AF647 (Jackson ImmunoResearch, 109-605-098) on ice 
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for 4 min. Post labeling, the beads were washed once with ice-cold PBSB and evaluated by flow 
cytometry. 
Nanobody competition analysis 
To evaluate the epitope of KC3.ep3, competitive binding analysis was performed with other 
SARS-CoV-2 antibodies and nanobodies. Biotinylated RBD (5 nM) was first pre-incubated with 
soluble nanobodies/antibodies in the bivalent format or ACE2 (RayBiotech, 230-30165) over a 
range of concentrations (0.05, 0.5, 5, 50 and 500 nM) for 2 h at room temperature with mild 
agitation. Next, the antibody-antigen complexes were incubated with yeast cells expressing 
monovalent KC3.ep3, along with anti-Myc antibody (1000x dilution), in PBSB with 1% milk at 
room temperature for 3 h. Post incubation, cells were washed once with ice-cold PBSB and 
incubated with streptavidin AF647 (1000x dilution) and goat anti-mouse IgG AF488 (200x 
dilution) on ice for 4 min. Following secondary incubation, cells were washed once with ice-cold 
PBSB and analyzed by flow cytometry. 
Nanobody biophysical characterization 
Melting temperature analysis 
The melting temperatures of the proteins in this work were determined using differential 
scanning fluorimetry. Proteins were prepared at 0.12 mg/mL and mixed with Protein Thermal Shift 
Dye (Applied Biosystems, 4461146) at a volume ratio of 7:1 protein:dye to reach a final 
concentration of 1x dye. The protein-dye mixture was added to individual wells of a clear 384-
well plate. Background signals were determined from 2-3 wells of 1x PBS mixed with dye. 
Samples were submitted to the University of Michigan Advanced Genomics core for analysis. 
Samples were centrifuged in the 384-well plate at 1000-2000 rpm for 1 min. The plates were then 
inserted into an ABI Prism 7900HT Sequence Detection System (Applied Biosystems), and 
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thermal cycle conditions were set to examine increasing temperatures between 25-98 °C over a 
period of 45 min. Background signals were subtracted from samples, and melting temperatures 
were determined from the temperatures at which the maximum signals (first derivative equals zero) 
were observed. 
Analytical size-exclusion chromatography 
The purity of the proteins after the Protein A purification was evaluated using size-exclusion 
chromatography with a Shimadzu Prominence HPLC System outfitted with a LC-20AT pump, 
SIL-20AC autosampler and FRC-10A fraction collector. Proteins in 20 mM acetate (pH 5) were 
buffer exchanged into PBS (pH 7.4). For analytical SEC, 100 µL of protein sample (diluted to 0.1 
mg/mL) was loaded onto the column (Superdex 200 Increase 10/300 GL column; GE, 28990944) 
and analyzed at 0.75 mL/min using a PBS running buffer supplemented with 200 mM arginine 
(pH 7.4). Absorbance was monitored at 220 and 280 nm, and the 280 nm signal was primarily used 
for analysis. The percentage of protein monomer was evaluated by analyzing the area under the 
peak between 8 and 22 min (exclusion volume to solvent elution times). Proteins with less than 
90% monomer were further purified via size-exclusion chromatography. Protein fractions were 
collected, buffer exchanged into PBS (pH 7.4), filtered, aliquoted and stored at -80 ᵒC.  
Polyspecificity analysis 
The polyspecificity reagent (PSR) was prepared as previously (Xu et al., 2013). CHO cells 
(109, Gibco, A29133) were pelleted, the cell pellets were washed separately with PBSB and Buffer 
B (50 mM HEPES, 0.15 M NaCl, 2 mM CaCl2, 5 mM KCl, 5 mM MgCl2, 10% Glycerol, pH 7.2), 
and then pelleted again. The pellets were resuspended in 5 mL of Buffer B supplemented with a 
protease inhibitor (Sigma Aldrich, 4693159001). Next, the resuspended cells were homogenized 
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for 90 s (three cycles of 30 s) followed by sonication for 90 s (three cycles of 30 s). The cell 
suspension was then spun down at 40,000 xg for 1 h and the supernatant was discarded.   
The pellet, comprising the enriched membrane fraction, was resuspended in Buffer B with a 
Dounce homogenizer for 30 strokes. The protein concentration was determined using a detergent 
compatible protein assay kit (BioRad, 5000116). The enriched membrane fraction was diluted to 
a theoretical concentration of 1 mg/mL in solubilization buffer (pH 7.2), the latter of which 
contained 50 mM HEPES, 0.15 M NaCl, 2 mM CaCl2, 5 mM KCl, 5 mM MgCl2, 1% n-dodecyl-
b-D-maltopyranoside (Sigma Aldrich, D4641), and a protease inhibitor (Sigma Aldrich, 
11873580001). The solution was then mixed overnight (end-over-end) at 4 ᵒC. The soluble 
membrane protein fraction was centrifuged at 40,000 xg for 1 h and the supernatant was collected. 
The final concentration of supernatant was ~0.8-0.9 mg/mL.  
Sulfo-NHS-LC-biotin (Thermo Fisher Scientific, PI21335) was dissolved in distilled water at 
~11.5 mg/mL. Stock solution of Sulfo-NHS-LC-biotin (150 mL) and the PSR reagent (4.5 mL at 
0.8-0.9 mg/mL) were mixed via end-over-end mixing at room temperature (45 min). The reaction 
was quenched (10 mL of 1.5 M hydroxylamine at pH 7.2), and biotinylated PSR was aliquoted 
and stored at -80 ᵒC. 
Protein A magnetic beads (Invitrogen, 88846) were washed three times with PBSB and 
incubated with antibodies at a range of concentrations in 96-well plates (VWR, 650261) overnight 
at 4 ᵒC. The antibodies were purified either via one-step (Protein A) or two-step (Protein A 
followed by size-exclusion chromatography) purification methods. Protein immobilization 
concentrations ranged from 0.03x to 10x of saturation of reported bead binding capacity for IgGs. 
Protein concentrations were normalized by molarity to maintain the same Fc concentration and 
bead saturation. Next, the protein-coated beads were washed by centrifuging the 96-well plates at 
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2500 xg for 4 min and washed twice with PBSB. Afterward, the beads were resuspended with a 
10x diluted solution of biotinylated PSR and incubated on ice for 20 min. Beads were washed once 
with PBSB and incubated with 1000x diluted solution of streptavidin AF-647 (Invitrogen, S32357) 
and 1000x diluted solution of goat anti-human Fc F(ab’)2 AF-488 (Invitrogen, H10120) on ice (4 
min). Beads were washed once, resuspended in PBSB, and analyzed via flow cytometry. The 
antibody binding steps were performed in PBSB, and three independent repeats were performed. 
The control antibodies used were the variable regions of elotuzumab (specific control) and 
emibetuzumab (polyspecific control) grafted onto a common IgG1 framework, which results in 
differences in the antibodies we have evaluated and the actual clinical-stage drugs. The control 
antibodies were two-step purified (Protein A and SEC) and were used to normalize results from 
all replicates between 0 and 1.  
QUANTIFICATION AND STATISTICAL ANALYSIS 
 The number replicates performed for each experiment can be found in the figure caption. The 
average and standard deviation of the IC50, KD, and EC50 values are given in the figures. Curve 
fitting was performed in Python. The average and standard deviation of melting temperatures are 
given in the Results.  
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 Conclusion  
 
Antibodies are currently used for a variety of applications including diagnostic and 
therapeutic tools as well as reagents for several diseases and proteins. This has developed a lot of 
interest in designing, discovering and engineering antibodies for a wide range of applications. An 
antibody discovery campaign has three parts: discovery platform or methodology, antibody library 
design and antigen design and preparation. We think for a successful discovery campaign, it is 
imperative to have as much control as possible over all three parts. 
Traditionally, antibodies were isolated by immunization and to date it still remains as one 
of the most preferred techniques. Although immunization has a high success rate, it has multiple 
limitations like lack of control over antigen presentation and specificity for complex antigens, 
inability to perform counter-selections, targeting proteins with post translational-modifications and 
the need for humanizing antibodies for therapeutic and diagnostic applications.  
In vitro selection methods like phage, yeast, mammalian antibody display can used to 
overcome some of the limitations of immunizations. These techniques have been used successfully 
to isolate and further engineer several types of proteins including peptides, antibodies, antibody-
like fragments and enzymes. We have focused solely on in vitro selection technique of yeast 
surface display for our antibody isolation and engineering. Yeast is easily to work with compared 
to phase and mammalian systems. Further, yeast being eukaryotic, they have sophisticated 
machinery to make and display high quality proteins compared to phage. Also, co-selection of 
different properties simultaneously makes yeast surface display very attractive.  
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Yeast surface display mainly uses two methods for antibody selection: MACS (magnetic-
activated cell sorting) and FACS (florescence-activated cell sorting). Both the sorting methods 
have their advantages and drawbacks. FACS allows visualization and co-selection of two or more 
properties simultaneously whereas this is not possible for MACS. It is challenging to process large 
number of cells (>108) and perform selections against insoluble antigens like amyloid aggregates 
by FACS. Although MACS can be used for such an application, the overall efficiency of the 
selection process is low because of lack of control of selection process. Also, MACS offers highly 
avid surface for selection which might make selections for intrinsic affinity tricky. This problem 
is further aggravated since amyloid fibrils are multivalent in nature. Many of the above challenges 
motivated us to design a novel nanoparticle-based selection technique where amyloid aggregates 
can be used with flow cytometry and/or FACS. Such a selection technique is reported here for the 
first time (at least to our understanding) and used successfully. But we do suspect this selection 
technique can be further improved by optimization. 
Antibody library design is very crucial for a successful discovery campaign. Although, a 
library can be designed in several different ways, some methods might be more attractive than 
others in terms of library designs and constructions. We have successfully used multiple different 
design strategies like directed mutagenesis using natural diversity and NNK codons, error-prone 
PCR, naïve non-immune libraries, CDR swapping mutagenesis and so on. Many times, we have 
used combinations of different strategies to engineer high performance antibodies.  
One of our goals was to design robust methods to isolate conformational antibodies against 
amyloid aggregates. Although conformational antibodies have been isolated successfully by 
immunization, we preferred yeast surface display for several reasons discussed above.  Using our 
novel library designs and selection methods, we were successfully able to isolate and engineered 
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conformational antibodies whose properties rival or are better than several clinical stage antibodies 
and approved drug for disorders like Alzheimer’s and Parkinson’s disease. Our conformational Aβ 
antibodies have affinity (EC50 – 2-12 nM) and conformational specificity similar to drug 
Aducanumab but substantially lower non-specific binding. Our conformational tau antibodies have 
affinity (EC50 – 0.5-1 nM) and conformational specificity similar to clinical antibody 
Zagotanemab. Our conformational α-synuclein antibody have  similar affinity (EC50 - 10-20 nM) 
but superior conformational specificity compared to clinical antibody Cinpanemab. Our antibodies 
work well against aggregates formed in vitro and in vivo from transgenic mice and human brains. 
We think this is remarkable since the antibodies were generated strictly using in vitro aggregates 
but show similar activity against pathological in vivo formed aggregates. Further, our antibodies 
can be used in variety of formats like ELISA, immunodot and western blots and 
immunofluorescence assays. Also, all our antibodies and antibody fragments are very stable and 
can be easily expressed in mammalian cells with high quality and quantity. All the data we 
generated and presented is either with in vitro assays or using biological samples in in vitro assays. 
It would be highly interesting and informative to see how our conformational antibodies work in 
in vivo studies. It would be attractive to test our antibodies in mouse models for Alzheimer’s or 
Parkinson’s disease to see if they can help reduce the plaque loads in brains and help with delay 
or reversal of symptoms. This is particularly interesting since the conformational antibodies were 
made with therapeutic applications in mind. Also, since our antibodies have a range of properties 
which are different from clinical antibodies and approved drugs, it would be informative to see 
how their affect in vivo properties. 
We also successfully isolated and engineered antibody fragments against SARS-CoV-2 
using yeast surface display. All our engineered nanobodies show high affinity, high specificity and 
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neutralization activity in pseudovirus assay. Further, our best nanobody can neutralize live SARS-
CoV-2 potently. Although the discovery of our affinity matured clones which showed CDR 
swapping was unintentional, we intentionally performed CDR swapping mutagenesis, isolated 
more antibodies and evaluated them. We demonstrated that antibodies where CDRs were swapped 
showed large increase in affinity and neutralization potency compared to lead parent antibodies. 
This result is particularly exciting since we can generate high quality lead antibodies without 
affinity maturation. To further test the robustness of this approach, we exploited this idea of CDR 
loop swapping for our tau conformational antibodies where we combined beneficial mutations 
from three binding loops and generated antibodies with high affinity and conformational 
specificity. It would also be very interesting to evaluate if our antibodies can bind and neutralize 
the different strains of SARS-CoV-2 including the U.K, Brazilian and South African strains. The 
mutation of SARS-CoV-2 has rendered many monoclonal antibodies useless and also decreased 
the efficiency of the vaccination. This is mainly because of the mutations in RBD and other regions 
of the spike protein which knocked-out the binding. It would be very attractive to make broadly 
neutralizing class of antibodies which would bind to conserved regions in SARS-CoV-2 so the 
neutralizing activity is retained against different strains. Also, this would help guide the design of 
next generation of vaccines and help us get ready for future pandemics. 
Lastly, therapies are direly needed for several disorders like Alzheimer’s and Parkinson’s 
disease. We do hope that the above work on isolating and engineering conformational antibodies 
could lay the foundations for more robust selection methods which would further accelerate the 
discovery and engineering of conformational antibodies against several different protein 
aggregates. 
